

# Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness

Barbara H. Stokes, Satish K. Dhingra, Kelly Rubiano, Sachel Mok, Judith Straimer, Nina F. Gnadig, Ioanna Deni, Kyra A. Schindler, Jade R. Bath, Kurt E. Ward, et al.

# ▶ To cite this version:

Barbara H. Stokes, Satish K. Dhingra, Kelly Rubiano, Sachel Mok, Judith Straimer, et al.. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. eLife, eLife Sciences Publication, 2021, 10, pp.e66277. 10.7554/eLife.66277 . pasteur-03291682

# HAL Id: pasteur-03291682 https://hal-riip.archives-ouvertes.fr/pasteur-03291682

Submitted on 19 Jul 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution | 4.0 International License

# *Plasmodium falciparum* K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness

3

Barbara H. Stokes<sup>1</sup>, Satish K. Dhingra<sup>1</sup>, Kelly Rubiano<sup>1</sup>, Sachel Mok<sup>1</sup>, Judith Straimer<sup>1</sup>, Nina F. Gnädig<sup>1</sup>, Ioanna
Deni<sup>1</sup>, Kyra A. Schindler<sup>1</sup>, Jade R. Bath<sup>1</sup>, Kurt E. Ward<sup>1,2</sup>, Josefine Striepen<sup>1</sup>, Tomas Yeo<sup>1</sup>, Leila S. Ross<sup>1</sup>, Eric
Legrand<sup>3</sup>, Frédéric Ariey<sup>4</sup>, Clark H. Cunningham<sup>1,5</sup>, Issa M. Souleymane<sup>6</sup>, Adama Gansané<sup>7</sup>, Romaric
Nzoumbou-Boko<sup>8</sup>, Claudette Ndayikunda<sup>9</sup>, Abdunoor M. Kabanywanyi<sup>10</sup>, Aline Uwimana<sup>11</sup>, Samuel J. Smith<sup>12</sup>,
Olimatou Kolley<sup>13</sup>, Mathieu Ndounga<sup>14</sup>, Marian Warsame<sup>15</sup>, Rithea Leang<sup>16</sup>, François Nosten<sup>17,18</sup>, Timothy J.C.
Anderson<sup>19</sup>, Philip J. Rosenthal<sup>20</sup>, Didier Ménard<sup>3</sup>, David A. Fidock<sup>1,21‡</sup>

10

11 <sup>1</sup>Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA; <sup>2</sup>Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand; <sup>3</sup> Malaria Genetics 12 and Resistance Unit, Institut Pasteur, INSERM U1201, CNRS ERL9195, Paris, France; <sup>4</sup>Institut Cochin INSERM 13 U1016, Université Paris Descartes, Paris, France; <sup>5</sup>Department of Genetics, University of North Carolina at 14 Chapel Hill, Chapel Hill, NC, USA; <sup>6</sup>Programme National de Lutte Contre le Paludisme au Tchad, Ndjamena, 15 Chad; <sup>7</sup>Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso; 16 <sup>8</sup>Laboratory of Parasitology, Institute Pasteur of Bangui, Bangui, Central African Republic; <sup>9</sup>University Teaching 17 Hospital of Kamenge, Bujumbura, Burundi; <sup>10</sup>Ifakara Health Institute, Dar es Salaam, Tanzania; <sup>11</sup>Malaria and 18 Other Parasitic Diseases Division, Rwanda Biomedical Centre, Kigali, Rwanda; <sup>12</sup>National Malaria Control 19 Programme, Sierra Leone: <sup>13</sup>National Malaria Control Program, Banjul, The Gambia; <sup>14</sup>Programme National de 20 Lutte Contre le Paludisme, Brazzaville, République du Congo; <sup>15</sup>School of Public Health and Community 21 Medicine, University of Gothenburg, Sweden; <sup>16</sup>National Center for Parasitology, Entomology & Malaria Control, 22 Phnom Penh, Cambodia; <sup>17</sup>Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, 23 Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand; <sup>18</sup>Centre for Tropical Medicine and Global 24 Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; <sup>19</sup>Texas Biomedical Research 25 Institute, San Antonio, TX, USA; <sup>20</sup>Department of Medicine, University of California, San Francisco, CA, USA; 26 27 <sup>21</sup>Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New 28 York, NY, USA

29 <sup>‡</sup>Corresponding author. Email: df2260@cumc.columbia.edu

# 30 Abstract

31 The emergence of mutant K13-mediated artemisinin (ART) resistance in Plasmodium falciparum malaria 32 parasites has led to widespread treatment failure across Southeast Asia. In Africa, K13-propeller genotyping 33 confirms the emergence of the R561H mutation in Rwanda and highlights the continuing dominance of wild-type 34 K13 elsewhere. Using gene editing, we show that R561H, along with C580Y and M579I, confer elevated in vitro 35 ART resistance in some African strains, contrasting with minimal changes in ART susceptibility in others. C580Y 36 and M579I cause substantial fitness costs, which may slow their dissemination in high-transmission settings, in 37 contrast with R561H that in African 3D7 parasites is fitness neutral. In Cambodia, K13 genotyping highlights the 38 increasing spatio-temporal dominance of C580Y. Editing multiple K13 mutations into a panel of Southeast Asian 39 strains reveals that only the R561H variant yields ART resistance comparable to C580Y. In Asian Dd2 parasites 40 C580Y shows no fitness cost, in contrast with most other K13 mutations tested, including R561H. Editing point 41 mutations in *ferredoxin* or *mdr2*, earlier associated with resistance, has no impact on ART susceptibility or 42 parasite fitness. These data underline the complex interplay between K13 mutations, parasite survival, growth 43 and genetic background in contributing to the spread of ART resistance.

# 44 Introduction

45 Despite recent advances in chemotherapeutics, diagnostics and vector control measures, malaria continues to 46 exert a significant impact on human health (Hanboonkunupakarn and White, 2020). In 2019, cases were 47 estimated at 229 million, resulting in 409,000 fatal outcomes, primarily in Sub-Saharan Africa as a result of 48 Plasmodium falciparum infection (WHO, 2020). This situation is predicted to worsen as a result of the ongoing 49 SARS-CoV-2 pandemic that has compromised malaria treatment and prevention measures (Sherrard-Smith et 50 al., 2020). Absent an effective vaccine, malaria control and elimination strategies are critically reliant on the 51 continued clinical efficacy of first-line artemisinin-based combination therapies (ACTs) (White et al., 2014). 52 These ACTs pair fast-acting artemisinin (ART) derivatives with partner drugs such as lumefantrine, 53 amodiaquine, mefloquine or piperaquine (PPQ). ART derivatives can reduce the biomass of drug-sensitive 54 parasites by up to 10,000-fold within 48 h (the duration of one intra-erythrocytic developmental cycle); however, 55 these derivatives are rapidly metabolized in vivo. Longer-lasting albeit slower-acting partner drugs are co-56 administered to reduce the selective pressure for ART resistance and to clear residual parasitemias (Eastman 57 and Fidock, 2009).

58

59 P. falciparum resistance to ART derivatives has now swept across Southeast (SE) Asia, having first emerged a 60 decade ago in western Cambodia (Dondorp et al., 2009; Noedl et al., 2009; Ariey et al., 2014; Imwong et al., 61 2020). Clinically, ART resistance manifests as delayed clearance of circulating asexual blood stage parasites 62 following treatment with an ACT but does not result in treatment failure as long as the partner drug remains 63 effective. The accepted threshold for resistance is a parasite clearance half-life (the time required for the 64 peripheral blood parasite density to decrease by 50%) of >5.5 h. Sensitive parasites are typically cleared in <2-3 65 h (WHO, 2019). Resistance can also be evidenced as parasite-positive blood smears on day three post initiation 66 of treatment. In vitro, ART resistance manifests as an increase in survival in tightly synchronized ring-stage 67 parasites (0-3 h post invasion) exposed to a 6 h pulse of 700 nM dihydroartemisinin (DHA, the active metabolite 68 of all ARTs used clinically) in the ring-stage survival assay (RSA) (Witkowski et al., 2013; Ariey et al., 2014). 69 Recently, ART-resistant strains have also acquired resistance to PPQ, which is widely used in SE Asia as a 70 partner drug in combination with DHA (Wicht et al., 2020). Failure rates following DHA-PPQ treatment now 71 exceed 50% in parts of Cambodia, Thailand and Vietnam (van der Pluijm et al., 2019).

73 In vitro selections, supported by clinical epidemiological data, have demonstrated that ART resistance is 74 primarily determined by mutations in the beta-propeller domain of the P. falciparum Kelch protein K13, also 75 known as Kelch13 (Ariey et al., 2014; Ashley et al., 2014; MalariaGEN, 2016; Menard et al., 2016; Siddigui et 76 al., 2020). Recent evidence suggests that these mutations result in reduced endocytosis of host-derived hemoglobin and thereby decrease the release of Fe<sup>2+</sup>-heme that serves to activate ART, thus reducing its 77 78 potency (Yang et al., 2019; Birnbaum et al., 2020). Mutations in other genes including ferredoxin (fd) and 79 multidrug resistance protein 2 (mdr2) have also been associated with ART resistance in K13 mutant parasites, 80 leading to the suggestion that they either contribute to a multigenic basis of resistance or fitness or serve as 81 genetic markers of founder populations (Miotto et al., 2015).

82

72

83 In SE Asia, the most prevalent K13 mutation is C580Y, which associates with delayed clearance in vivo (Ariev et al., 2014; Ashley et al., 2014; MalariaGEN, 2016; Menard et al., 2016; Imwong et al., 2017). This mutation also 84 85 mediates ART resistance in vitro, as demonstrated by RSAs performed on gene-edited parasites (Ghorbal et al., 86 2014; Straimer et al., 2015; Straimer et al., 2017; Mathieu et al., 2020; Uwimana et al., 2020). Other studies 87 have documented the emergence of nearly 200 other K13 mutations, both in SE Asia and in other malaria-88 endemic regions, including the Guiana Shield and the western Pacific (MalariaGEN, 2016; Menard et al., 2016; 89 Das et al., 2019; WWARN, 2019; Mathieu et al., 2020; Miotto et al., 2020). Aside from C580Y, however, only a 90 handful of K13 mutations (N458Y, M476I, Y493H, R539T, I543T and R561H) have been validated by gene-91 editing experiments as conferring resistance in vitro (Straimer et al., 2015; Siddigui et al., 2020). Nonetheless, 92 multiple other mutations in this gene have been associated with the clinical delayed clearance phenotype and 93 have been proposed as candidate markers of ART resistance (WWARN, 2019; WHO, 2019).

94

Here, we define the role of a panel of K13 mutations identified in patient isolates, and address the key question of whether these mutations can confer resistance in African strains. We include the K13 R561H mutation, earlier associated with delayed parasite clearance in SE Asia (Ashley *et al.*, 2014; Phyo *et al.*, 2016), and very recently identified at up to 13% prevalence in certain districts in Rwanda (Uwimana *et al.*, 2020; Bergmann *et al.*, 2021; Uwimana *et al.*, 2021). This study also enabled us to assess the impact of the parasite genetic background on *in vitro* phenotypes, including mutations in *ferredoxin* and *mdr2* that were earlier associated with resistance (Miotto

*et al.*, 2015). Our results show that K13 mutations can impart ART resistance across multiple Asian and African
 strains, at levels that vary widely depending on the mutation and the parasite genetic background. Compared
 with K13 mutant Asian parasites, we observed stronger *in vitro* fitness costs in most K13-edited African strains,
 which might predict a slower dissemination of ART resistance in high-transmission African settings.
 Nonetheless, our data highlight the threat of the R561H mutation emerging in Rwanda, which confers elevated
 RSA resistance and minimal fitness cost in African 3D7 parasites.

107

# 108 **Results**

109 Non-synonymous K13 mutations are present at low frequencies in Africa

To examine the status of K13 mutations across Africa, we analyzed *K13* beta-propeller domain sequences in 3,257 isolates from 11 malaria-endemic African countries, including The Gambia, Sierra Leone, and Burkina Faso in West Africa; Chad, Central African Republic, Republic of the Congo, and Equatorial Guinea in Central Africa; and Burundi, Tanzania, Rwanda, and Somalia in East Africa. Samples were collected between 2012 and 2019, with most countries sampled across multiple years. 1,038 (32%) originated from The Gambia, Republic of the Congo and Burundi and have not been previously reported, whereas the remaining samples including those from Rwanda have been published (**Figure 1–Source data 1; Supplementary file 1**).

117

Of all samples, 98% (3,179) were K13 wild-type, i.e. they matched the 3D7 (African) reference sequence or harbored a synonymous (non-coding) mutation. For individual countries, the percentage of K13 wild-type samples ranged from 95% to 100% (**Figure 1; Figure 1–source data 1**). In total, we identified 35 unique nonsynonymous mutations in K13. Of these, only two have been validated as resistance mediators in the SE Asian Dd2 strain: the M476I mutation initially identified from long-term ART selection studies and the R561H mutation observed in SE Asia and Rwanda (Ariey *et al.*, 2014; Straimer *et al.*, 2015; Uwimana *et al.*, 2020).

124

Of the 35 non-synonymous mutations, only two were present in >6 samples: R561H (n=20, found only in Rwanda, sampled from 2012 to 2015; (Uwimana *et al.*, 2020)), and A578S (n=10; observed in four African countries across multiple years). Previously A578S was shown not to confer *in vitro* resistance in Dd2 (Menard

*et al.*, 2016). In the set of 927 genotyped Rwandan isolates, R561H accounted for 44% of mutant samples and
2% of all samples (Figure 1 inset).

130

#### 131 K13 R561H, M579I and C580Y mutations can confer *in vitro* artemisinin resistance in African parasites

132 To test whether R561H can mediate ART resistance in African strains, we developed a CRISPR/Cas9-mediated 133 K13 editing strategy (Supplementary file 2) to introduce this mutation into 3D7 and F32 parasites. On the basis 134 of whole-genome sequence analysis of African isolates, 3D7 was recently shown to segregate phylogenetically 135 with parasites from Rwanda (Ariey et al., 2014; Uwimana et al., 2020). F32 was derived from an isolate from 136 Tanzania (Witkowski et al., 2010). We also tested the C580Y mutation that predominates in SE Asia, as well as 137 the M579I mutation earlier identified in a P. falciparum-infected migrant worker in Equatorial Guinea who 138 displayed delayed parasite clearance following ACT treatment (Lu et al., 2017). The positions of these residues 139 are highlighted in the K13 beta-propeller domain structure shown in **Supplementary file 3**. For 3D7, F32 and 140 other lines used herein, their geographic origins and genotypes at drug resistance loci are described in Table 1 141 and Supplementary file 4. All parental lines were cloned by limiting dilution prior to transfection. Edited 142 parasites were identified by PCR and Sanger sequencing, and cloned. These and other edited parasite lines 143 used herein are described in **Supplementary file 5**.

144

145 RSAs, used to measure in vitro ART susceptibility, revealed a wide range of mean survival values for K13 mutant lines. For 3D7 parasites, the highest RSA survival rates were observed with 3D7<sup>R561H</sup> parasites, which 146 averaged 6.6% RSA survival. For the 3D7<sup>M579I</sup> and 3D7<sup>C580Y</sup> lines, mean RSA survival rates were both 4.8%, a 3 147 to 4-fold increase relative to the 3D7<sup>WT</sup> line. No elevated RSA survival was seen in a 3D7 control line (3D7<sup>ctrl</sup>) 148 149 that expressed only the silent shield mutations used at the guide RNA cut site (Figure 2A; Figure 2-source data 1). Western blot analysis with tightly synchronized ring-stage parasites revealed a ~30% reduction in K13 150 protein expression levels in these three K13 mutant lines relative to the parental 3D7<sup>WT</sup> (Figure 2-figure 151 152 supplement 1; Figure 2-figure supplement 1-source data 1).

153

Interestingly, for F32 parasites the introduction of K13 mutations yielded no significant increase in RSA survival,
whose rates were in the range of 0.3% to 0.5% for lines expressing R561H, M579I, C580Y or wild-type K13.
(Figure 2B). Previously we reported that introduction of M476I into F32 parasites resulted in a modest gain of

resistance (mean survival of 1.7%) while this same mutation conferred RSA survival levels of ~10% in edited Dd2 parasites (Straimer *et al.*, 2015). These data suggest that while K13 mutations differ substantially in their impact on ART susceptibility, there is an equally notable contribution of the parasite genetic background.

160

161 We next introduced M579I and C580Y into cloned Ugandan isolates UG659 and UG815. Editing of both mutations into UG659 yielded moderate RSA survival rates (means of 6.3% and 4.7% for UG659<sup>M579I</sup> or 162 UG659<sup>C580Y</sup> respectively, vs. 1.0% for UG659<sup>WT</sup>; Figure 2C). These values resembled our results with 3D7. 163 164 Strikingly, introducing K13 M579I or C580Y into UG815 yielded the highest rates of in vitro resistance, with mean survival levels reaching ~12% in both UG815<sup>M579I</sup> and UG815<sup>C580Y</sup>. These results were confirmed in a 165 second independent clone of UG815<sup>M579I</sup> (Figure 2D). M579I and C580Y also conferred equivalent levels of 166 167 resistance in edited Dd2 parasites (RSA survival rates of 4.0% and 4.7%, respectively; Figure 2-source data 168 1). These data show that mutant K13-mediated ART resistance in African parasites can be achieved, in some 169 but not all strains, at levels comparable to or above those seen in SE Asian parasites.

170

171 K13 C580Y and M579I mutations, but not R561H, are associated with an *in vitro* fitness defect across
 172 African parasites

To examine the relation between resistance and fitness in African parasites harboring K13 mutations, we developed an *in vitro* fitness assay that uses quantitative real-time PCR (qPCR) for allelic discrimination. Assays were conducted by pairing K13 wild-type lines (i.e. 3D7, F32, UG659 and UG815) with their isogenic edited R561H, M579I, or C580Y counterparts.

177

Assays were initiated with tightly synchronized trophozoites, mixed in 1:1 ratios of wild-type to mutant isogenic parasites, and cultures were maintained over a period of 36 days (~18 generations of asexual blood stage growth). Cultures were sampled every four days for genomic DNA (gDNA) preparation and qPCR analysis. TaqMan probes specific to the *K13* wild-type or mutant (R561H, M579I or C580Y) alleles were used to quantify the proportion of each allele.

183

184 Results showed that the K13 M579I and C580Y mutations each conferred a significant fitness defect across
 185 most strains tested, with the proportions of K13 mutant lines declining over time. For both mutations, the largest

186 reductions were observed with edited 3D7 or UG815 parasites. In contrast, these mutations exerted a minimal 187 impact on fitness in UG659. For R561H, we observed no impact on fitness in 3D7 parasites, although in F32 this 188 mutation exerted a fitness defect similar to M579I and C580Y (Figure 3A-D; Figure 3-source data 1). From 189 these data, we calculated the fitness cost, which represents the percent reduction in growth rate per 48 h 190 deneration of a test line compared to its wild-type isodenic comparator. These costs ranged from <1% to 12% per generation across mutations and lines, with the lowest costs observed in 3D7<sup>R561H</sup> and UG659<sup>C580Y</sup>, and the 191 greatest cost observed with K13-edited UG815 lines (Figure 3E). Comparing data across these four African 192 193 strains revealed that high RSA survival rates were generally accompanied by high fitness costs, and conversely that low fitness costs were associated with low survival rates. An exception was 3D7<sup>R561H</sup> that showed moderate 194 195 resistance with no apparent fitness cost (Figure 3F).

196

#### 197 The K13 C580Y mutation has swept rapidly across Cambodia, displacing other K13 variants

198 We next examined the spatio-temporal distribution of K13 alleles in Cambodia, the epicenter of ART resistance 199 in SE Asia. In total, we analyzed the K13 propeller domain sequences from 3,327 parasite isolates collected 200 from western, northern, eastern and southern Cambodian provinces (Figure 4-figure supplement 1). Samples 201 were collected between 2001 and 2017, except for the southern region where sample collection was initiated in 202 2010. 1,412 samples (42%) were obtained and sequenced during the period 2015-2017 and have not previously 203 been published. Earlier samples were reported in (Ariey et al., 2014; Menard et al., 2016). In sum, 19 204 nonsynonymous polymorphisms in K13 were identified across all regions and years. Of these, only three were present in >10 samples: Y493H (n=83), R539T (n=87) and C580Y (n=1,915). Each of these mutations was 205 206 previously shown to confer ART resistance in vitro (Straimer et al., 2015). Rarer mutations included A418V, 207 1543T, P553L, R561H, P574L, and D584V (Figure 4; Figure 4-source data 1).

208

This analysis revealed a significant proportion of K13 wild-type parasites in the early 2000s, particularly in northern and eastern Cambodia, where 96% of isolates in 2001-2002 were wild type (**Figure 4**). In western Cambodia, where ART resistance first emerged (Dondorp *et al.*, 2009; Noedl *et al.*, 2009), the wild-type allele percentage in 2001-2002 had already fallen to 56%. This is striking given that delayed parasite clearance following ACT or artesunate treatment was first documented in 2008-2009 (Noedl *et al.*, 2008; Noedl *et al.*, 2009).

In all four regions, the frequency of the wild-type allele declined substantially over time and the diversity of mutant alleles contracted, with nearly all wild-type and non-K13 C580Y mutant parasites being replaced by parasites harboring the C580Y mutation (**Figure 4**). This effect was particularly pronounced in the west and the south, where the prevalence of C580Y in 2016-17 effectively attained 100%, increasing from 22% and 58% respectively in the initial sample sets (**Figure 4A, D**). In northern and eastern Cambodia, C580Y also outcompeted all other mutant alleles; however, 19-25% of parasites remained K13 wild type in 2016-17 (**Figure 4B, C**). These data show rapid dissemination of K13 C580Y across Cambodia.

223

215

224 SE Asian K13 mutations associated with delayed parasite clearance differ substantially in their ability to 225 confer artemisinin resistance *in vitro* 

226 Given that most K13 polymorphisms present in the field have yet to be characterized in vitro, we selected a set 227 of mutations to test by gene editing, namely E252Q, F446I, P553L, R561H and P574L (highlighted in 228 Supplementary file 3). F446l is the predominant mutation in Myanmar (Imwong et al., 2020). P553L, R561H 229 and P574L have each been shown to have multiple independent origins throughout SE Asia (Menard et al., 230 2016), and were identified at low frequencies in our sequencing study in Cambodia (Figure 4). Lastly, the 231 E252Q mutation was formerly prevalent on the Thai-Myanmar border, and, despite its occurrence upstream of 232 the beta-propeller domain, has been associated with delayed parasite clearance in vivo (Anderson et al., 2017; 233 Cerqueira et al., 2017; WWARN, 2019).

234

Zinc-finger nuclease- or CRISPR/Cas9-based gene-edited lines expressing K13 E252Q, F4461, P553L, R561H
or P574L were generated in Dd2 or Cam3.II lines expressing wild-type K13 (Dd2<sup>WT</sup> or Cam3.II<sup>WT</sup>) and
recombinant parasites were cloned. Early ring-stage parasites were then assayed for their ART susceptibility
using the RSA. For comparison, we included published Dd2 and Cam3.II lines expressing either K13 C580Y
(Dd2<sup>C580Y</sup> and Cam3.II<sup>C580Y</sup>) or R539T (Dd2<sup>R539T</sup> and the original parental line Cam3.II<sup>R539T</sup>) (Straimer *et al.*,
2015), as well as control lines expressing only the guide-specific silent shield mutations (Dd2<sup>ctrl</sup> and Cam3.II<sup>ctrl</sup>).

241

Both the P553L and R561H mutations yielded mean RSA survival rates comparable to C580Y (4.6% or 4.3%
 RSA survival for Dd2<sup>P553L</sup> or Dd2<sup>R561H</sup>, respectively, vs 4.7% for Dd2<sup>C580Y</sup>; Figure 5A; Figure 5-source data 1).

F446I and P574L showed only modest increases in survival relative to the wild-type parental line (2.0% and 2.1% for  $Dd2^{F446I}$  and  $Dd2^{P574L}$ , respectively, vs 0.6% for  $Dd2^{WT}$ ). No change in RSA survival relative to  $Dd2^{WT}$ was observed for the  $Dd2^{E252Q}$  line. The resistant benchmark  $Dd2^{R539T}$  showed a mean RSA survival level of 20.0%, consistent with earlier reports of this mutation conferring high-grade ART resistance *in vitro* (Straimer *et al.*, 2015; Straimer *et al.*, 2017).

249

In contrast to Dd2, editing of the F446I, P553L and P574L mutations into Cambodian Cam3.II<sup>WT</sup> parasites did 250 251 not result in a statistically significant increase in survival relative to the K13 wild-type line, in part because the background survival rate of Cam3.II<sup>WT</sup> was higher than for Dd2<sup>WT</sup>. All survival values were <3%, contrasting with 252 the Cam3.II<sup>R539T</sup> parental strain that expresses the R539T mutation (~20% mean survival; Figure 5B; Figure 5-253 254 source data 1). The E252Q mutation did not result in elevated RSA survival in the Cam3.II background, a result also observed with Dd2. Nonetheless, ART resistance was apparent upon introducing the R561H mutation into 255 Cam3.II<sup>WT</sup> parasites, whose mean survival rates exceeded the Cam3.II<sup>C580Y</sup> line (13.2% vs 10.0%, respectively). 256 No elevated survival was seen in the Cam3.II<sup>ctrl</sup> line expressing only the silent shield mutations used at the guide 257 258 RNA cut site.

259

#### 260 SE Asian K13 mutations do not impart a significant fitness impact on Dd2 parasites

261 Prior studies with isogenic gene-edited SE Asian lines have shown that certain K13 mutations can exert fitness 262 costs, as demonstrated by reduced intra-erythrocytic asexual blood stage parasite growth (Straimer et al., 2017; Nair et al., 2018). To determine the fitness impact of the K13 mutations described above, we utilized an eGFP-263 based parasite competitive growth assay (Ross et al., 2018). Dd2<sup>E252Q</sup>, Dd2<sup>F446I</sup>, Dd2<sup>P553L</sup>, Dd2<sup>R561H</sup> or Dd2<sup>P574L</sup> 264 265 were co-cultured with an isogenic K13 wild-type eGFP<sup>+</sup> Dd2 reporter line at a starting ratio of 1:1. The proportion of eGFP<sup>+</sup> parasites was then assessed every two days. As controls, we included Dd2<sup>WT</sup>, Dd2<sup>bsm</sup> and Dd2<sup>C580Y</sup>. 266 267 These data provided evidence of a minimal impact with the F446I, P553L and C580Y mutations, with E252Q, R561H and P574L having greater fitness costs when compared to Dd2<sup>WT</sup> (Figure 5C; Figure 5-figure 268 269 supplement 1; Figure 5-source data 2). Both C580Y and P553L displayed elevated RSA survival and minimal 270 fitness cost in the Dd2 strain, providing optimal traits for dissemination (Figure 5D). We note that all fitness 271 costs in Dd2 were considerably lower than those observed in our four African strains (Figure 3).

#### 273 Strain-dependent genetic background differences significantly impact RSA survival rates in culture-

#### 274 adapted Thai isolates

275 Given the earlier abundance of the R561H and E252Q alleles in border regions of Thailand and Myanmar, we 276 next tested the impact of introducing these mutations into five Thai K13 wild-type isolates (Thai1-5). For 277 comparison, we also edited C580Y into several isolates. These studies revealed a major contribution of the parasite genetic background in dictating the level of mutant K13-mediated ART resistance, as exemplified by the 278 279 C580Y lines whose mean survival rates ranged from 2.1% to 15.4%. Trends observed for individual mutations 280 were maintained across strains, with the R561H mutation consistently yielding moderate to high in vitro 281 resistance at or above the level of C580Y. Consistent with our Dd2 results, introducing E252Q did not result in 282 significant increases in survival rates relative to isogenic K13 wild-type lines (Figure 6A-E; Figure 6-source data 1). 283

#### 284

We also profiled two unedited culture-adapted Thai isolates (Thai6<sup>E252Q</sup> and Thai7<sup>E252Q</sup>) that express the K13 E252Q mutation upstream of the propeller domain. Notably, both lines exhibited mean RSA survival rates significantly above the 1% threshold for ART sensitivity (2.7% for Thai6<sup>E252Q</sup> and 5.1% for Thai7<sup>E252Q</sup>; **Figure 6F**). These data suggest that additional genetic factors present in these two Thai isolates are required for E252Q to manifest ART resistance.

290

# 291 Mutations in the *P. falciparum multidrug resistance protein 2* and *ferredoxin* genes do not modulate 292 resistance to artemisinin or parasite fitness *in vitro*

293 In a prior genome-wide association study of SE Asian parasites, K13-mediated ART resistance was associated 294 with D193Y and T484I mutations in the ferredoxin (fd) and multidrug resistance protein 2 (mdr2) genes, 295 respectively (Miotto et al., 2015). To directly test their role, we applied CRISPR/Cas9 editing (Supplementary 296 file 6) to revert the fd D193Y and mdr2 T484I mutations to the wild-type sequences in the Cambodian strains RF7<sup>C580Y</sup> and Cam3.II<sup>C580Y</sup>, which both express K13 C580Y. Isogenic RF7<sup>C580Y</sup> parasites expressing the mutant 297 298 or wild-type fd residue at position 193 showed no change in RSA survival rates, either at 700 nM (averaging ~27%), or across a range of DHA concentrations down to 1.4 nM (Figure 7A, C; Figure 7-figure supplement 299 1; Figure 7-source data 1). Editing fd D193Y into the recombinant CamWT<sup>C580Y</sup> line that expresses K13 300 301 C580Y (Straimer et al., 2015) also had no impact on RSA survival (with mean RSA survival rates of 11-13%).

Likewise, Cam3.II<sup>C580Y</sup> parasites maintained the same rate *of in vitro* RSA survival (mean 19-22%) irrespective of their *mdr2* allele. Silent shield mutations had no impact for either *fd* or *mdr2*. eGFP-based fitness assays initiated at different starting ratios of eGFP and either *fd*-edited RF7<sup>C580Y</sup> or *mdr2*-edited Cam3.II<sup>C580Y</sup> lines revealed no change in the growth rates of the *fd* or *mdr2* mutants compared with their wild-type controls (**Figure 7B, D; Figure 7–figure supplement 1; Figure 7–source data 2 and 3**). These data suggest that the fd D193Y and mdr2 T484I mutations are markers of ART-resistant founder populations but themselves do not contribute directly to ART resistance or augment parasite fitness.

309

## 310 **Discussion**

311 Mutant K13-mediated ART resistance has substantially compromised the efficacy of antimalarial treatments 312 across SE Asia (Hanboonkunupakarn and White, 2020), and the relatively high prevalence of the R561H variant 313 that has recently been associated with delayed clearance in Rwanda highlights the risk of ART resistance 314 emerging and spreading in sub-Saharan Africa (Uwimana et al., 2020; Bergmann et al., 2021; Uwimana et al., 315 2021). Using gene editing and phenotypic analyses, we provide definitive evidence that the K13 R561H, M579I 316 and C580Y mutations can confer in vitro ART resistance in several African strains. In vitro resistance, as defined 317 using the RSA, was comparable between gene-edited K13 R561H 3D7 parasites (originating from or near 318 Rwanda) and C580Y Dd2 and Cam3.II parasites (from SE Asia). Further investigations into edited African 3D7 319 parasites showed that these mutations also resulted in a ~30% decrease in K13 protein levels, consistent with 320 earlier studies into the mechanistic basis of mutant K13-mediated ART resistance (Birnbaum et al., 2017; 321 Siddiqui et al., 2017; Yang et al., 2019; Gnadig et al., 2020; Mok et al., 2021). We also observed that K13 322 mutant African strains differed widely in their RSA survival rates. As an example, when introduced into the 323 Tanzanian F32 strain, the C580Y mutation yielded a 0.3% RSA survival rate (not resistant), contrasting with 324 11.8% survival (highly resistant) in the Ugandan UG815 strain. These data suggest that F32 parasites lack 325 additional genetic determinants that are required for mutant K13 to confer ART resistance. Collectively, our 326 results provide evidence that certain African strains present no major biological obstacle to becoming ART 327 resistant in vitro upon acquiring K13 mutations. Further gene editing experiments are merited to extend these 328 studies to additional African strains, and to incorporate other variants such as C469Y and A675V that are 329 increasing in prevalence in Uganda (Asua et al., 2020).

331 Our mixed culture competition assays with African parasites revealed substantial fitness costs with the K13 332 C580Y mutation in three of the four strains tested (UG659 was the exception). The largest growth defect was 333 observed with the edited UG815 C580Y line, which also yielded the highest level of ART resistance in vitro. 334 These data suggest that K13 C580Y may not easily take hold in Africa where, unlike in SE Asia, infections are often highly polyclonal, generating intra-host competition that impacts a strain's ability to succeed at the 335 336 population level. In addition, individuals in highly-endemic African settings generally have high levels of acquired 337 immunity, potentially minimizing infection by relatively unfit parasites, and often have asymptomatic infections 338 that go untreated, and are thus less subject to selective drug pressure, compared with individuals in SE Asia 339 (Eastman and Fidock, 2009). This situation recalls the history of chloroquine use in Africa, where fitness costs 340 caused by mutations in the primary resistance determinant PfCRT resulted in the rapid resurgence of wild-type 341 parasites following the implementation of other first-line antimalarial therapies (Kublin et al., 2003; Laufer et al., 342 2006; Ord et al., 2007; Frosch et al., 2014).

343

344 An even greater fitness cost was observed with the M579I mutation, earlier detected in an infection acquired in 345 Equatorial Guinea with evidence of in vivo ART resistance (Lu et al., 2017) but which was notably absent in all 346 3,257 African samples reported herein. In contrast, we observed no evident fitness cost in 3D7 parasites 347 expressing the R561H variant, which might help contribute to its increasing prevalence in Rwanda. While our 348 Rwandan samples from 2012-2015 observed this mutation at 2% prevalence, samples collected by others in 349 2018 and 2019 identified this mutation at 12-13% prevalence (Bergmann et al., 2021; Uwimana et al., 2021). 350 One of these reports included evidence associating R561H with delayed parasite clearance in patients treated 351 with the ACT artemether-lumefantrine (Uwimana et al., 2021). These recent data heighten the concern that 352 mutant K13 might be taking hold in certain areas in in Africa where it can begin to compromise ACT efficacy.

353

In Cambodia, our spatio-temporal analysis of K13 sequence diversity highlights the initial emergence of C580Y in the western provinces, and its progressive replacement of other variants in the country. Interestingly, this mutation was already at high prevalence in western Cambodia several years before the first published reports of delayed parasite clearance in ART-treated patients (Noedl *et al.*, 2008; Dondorp *et al.*, 2009; Ariey *et al.*, 2014). The success of this mutation in Cambodia, and elsewhere in the eastern Greater Mekong subregion (Imwong *et* 

*al.*, 2020), cannot be explained by resistance alone, as we previously reported that the less common R539T and I543T variants conferred greater ART resistance *in vitro* (Straimer *et al.*, 2015). Similarly, we now report that the R561H and P553L mutations yield equivalent degrees of ART resistance in Dd2 parasites when compared with C580Y. In contrast, low-level resistance was observed with F446I, which has nonetheless spread across Myanmar (Imwong *et al.*, 2020). In a separate recent gene editing study, F446I yielded no significant *in vitro* resistance in 3D7 parasites and was fitness neutral (Siddiqui *et al.*, 2020), consistent with our findings for this mutation in edited Dd2 parasites.

366

367 Our studies into the impact of K13 mutations on in vitro growth in Asian Dd2 parasites provide evidence that that 368 the C580Y mutation generally exerts less of a fitness cost relative to other K13 variants, as measured in K13-369 edited parasites co-cultured with an eGFP reporter line. A notable exception was P553L, which compared with 370 C580Y was similarly fitness neutral and showed similar RSA values. P553L has nonetheless proven far less 371 successful in its regional dissemination compared with C580Y (Menard et al., 2016). These data suggest that 372 additional factors have contributed to the success of C580Y in sweeping across SE Asia. These might include 373 specific genetic backgrounds that have favored the dissemination of C580Y parasites, possibly resulting in 374 enhanced transmission potential (Witmer et al., 2020), or ACT use that favored the selection of partner drug 375 resistance in these parasite backgrounds (van der Pluijm et al., 2019). In terms of growth rates in our isogenic 376 Dd2 lines, the most detrimental impacts were observed with E252Q and R561H, which earlier predominated 377 near the Thailand-Myanmar border region, but were later overtaken by C580Y (Phyo et al., 2016). In our study, 378 C580Y produced an optimal combination of no measurable fitness cost and relatively high RSA survival rates in 379 Dd2 parasites. In a prior independent study however, R561H showed slightly improved fitness relative to C580Y 380 in paired isogenic parasites from Thailand (generated in the NHP4302 strain), providing further evidence that 381 both fitness and resistance are strain-dependent (Nair et al., 2018).

382

Further research is also required to define secondary genetic determinants that could augment mutant K13mediated ART resistance, and to explore other potential mediators of resistance. Proposed candidates have included *fd*, *mdr2*, *ap-2µ*, *ubp1* and *pfcoronin*, which have earlier been associated with *P. falciparum* ART susceptibility (Demas *et al.*, 2018; Henrici *et al.*, 2019; Sutherland *et al.*, 2020). Our data argue against a direct role for mutations in *fd* and *mdr2* in the strains tested herein. We also observed no evident association between

the genotypes of *pfcrt*, *pfmdr1*, *arps10*, *ap-2µ* or *ubp1* and the degree to which mutant K13 conferred ART resistance *in vitro* in our set of African or Asian strains (**Supplementary file 4**). Mutations associated with enhanced DNA repair mechanisms have also been observed in ART-resistant SE Asian parasites, supporting the idea that mutant K13 parasites may have an improved ability to repair ART-mediated DNA damage (Xiong *et al.*, 2020). Further studies are merited to investigate whether these DNA repair mutations may provide a favorable background for the development of ART resistance.

394

395 At the population level, we note that P. falciparum genomic structures in Africa tend to be far more diverse than 396 in the epicenter of resistance in Cambodia, where parasite strains are highly sub-structured into a few lineages 397 that can readily maintain complex genetic traits (Amato et al., 2018). A requirement to transmit mutant K13 and 398 additional determinants of resistance in African malaria-endemic settings, where genetic outcrossing is the 399 norm, would predict that ART resistance will spread more gradually in this continent than in SE Asia. It is 400 nonetheless possible that secondary determinants will allow some African strains to offset fitness costs 401 associated with mutant K13, or otherwise augment K13-mediated ART resistance. Identifying such determinants 402 could be possible using genome-wide association studies or genetic crosses between ART-resistant and 403 sensitive African parasites in the human liver-chimeric mouse model of P. falciparum infection (Vaughan et al., 2015; Amambua-Ngwa et al., 2019). Reduced transmission rates in areas of Africa where malaria is declining, 404 405 leading to lower levels of immunity, may also benefit the emergence and dissemination of mutant K13 (Conrad 406 and Rosenthal, 2019).

407

408 Another impediment to the dissemination of ART resistance in Africa is the continued potent activity of 409 lumefantrine, the partner drug in the first line treatment artemether-lumefantrine (Conrad and Rosenthal, 2019). 410 This situation contrasts with SE Asia where ART-resistant parasites have also developed high-level resistance 411 to the partner drug PPQ, with widespread treatment failures enabling the dissemination of multidrug-resistant 412 strains (Conrad and Rosenthal, 2019; van der Pluijm et al., 2019). While the genotyping data presented herein 413 and other recent molecular surveillance studies reveal low prevalence of mutant K13 in Africa (Kayiba et al., 414 2020; Schmedes et al., 2021), the emergence and spread of the R561H variant in Rwanda is cause for 415 significant concern. These data call for continuous continent-wide monitoring of the emergence and spread of

- 416 mutant K13 in Africa, and for studies into whether its emergence in Rwanda is a harbinger of subsequent
- 417 partner drug resistance and ACT treatment failure.

# 418 Materials and Methods

# 419 Key Resources Table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Gene ( <i>Plasmodium</i> <i>falciparum</i> 3D7 strain)	Kelch13 (K13)	PlasmoDB	PF3D7_1343700	
Gene ( <i>Plasmodium</i> <i>falciparum</i> 3D7 strain)	Ferredoxin (fd)	PlasmoDB	PF3D7_1318100	
Gene ( <i>Plasmodium</i> <i>falciparum</i> 3D7 strain)	Multidrug resistance protein 2 (mdr2)	PlasmoDB	PF3D7_1447900	
Strain, strain background ( <i>Plasmodium</i> falciparum)	3D7 clone A10 (3D7 <sup>WT</sup> )	D. Goldberg, Washington University School of Medicine, St. Louis, MO, USA		see <b>Table 1</b> and <b>Supplementary</b> <b>file 4</b> for additional details on all <i>P.</i> <i>falciparum</i> strains employed herein
Strain, strain background ( <i>Plasmodium</i> <i>falciparum</i> )	F32-TEM (F32 <sup>WT</sup> )	F. Benoit-Vical, Université de Toulouse, Toulouse, France (Ariey <i>et al.</i> , 2014)		
Strain, strain background ( <i>Plasmodium</i> <i>falciparum</i> )	UG659 (UG659 <sup>wt</sup> )	P. Rosenthal, University of California, San Francisco, CA, USA		
Strain, strain background ( <i>Plasmodium</i> <i>falciparum</i> )	UG815 (UG815 <sup>WT</sup> )	P. Rosenthal, University of California, San Francisco, CA, USA		
Strain, strain background ( <i>Plasmodium</i> <i>falciparum</i> )	Dd2 (Dd2 <sup>w⊺</sup> )	The Malaria Research and Reference Reagent Resource Center (MR4), BEI Resources	MRA-156	
Strain, strain background ( <i>Plasmodium</i> <i>falciparum</i> )	Cam3.II (Cam3.II <sup>R539T</sup> )	R. Fairhurst, NIAID, NIH, Bethesda, MD, USA (Straimer <i>et al.</i> , 2015)	PH0306-C	

Strain, strain background ( <i>Plasmodium</i> falciparum)	CamWT	R. Fairhurst, NIAID, NIH, Bethesda, MD, USA (Straimer <i>et al.</i> , 2015)	PH0164-C	
Strain, strain background ( <i>Plasmodium</i> falciparum)	RF7 (RF7 <sup>C580Y</sup> )	R. Fairhurst, NIAID, NIH, Bethesda, MD, USA (Ross <i>et al.</i> , 2018)	PH1008-C	
Strain, strain background ( <i>Plasmodium</i> falciparum)	Thai1 <sup>wT</sup>	T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA	TA32A2A4	
Strain, strain background ( <i>Plasmodium</i> falciparum)	Thai2 <sup>wτ</sup>	T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA	TA50A2B2	
Strain, strain background ( <i>Plasmodium</i> falciparum)	Thai3 <sup>w⊤</sup>	T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA	TA85R1	
Strain, strain background ( <i>Plasmodium</i> falciparum)	Thai4 <sup>w⊤</sup>	T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA	TA86A3	
Strain, strain background ( <i>Plasmodium</i> falciparum)	Thai5 <sup>wτ</sup>	T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA	NHP-01334-6B	
Strain, strain background ( <i>Plasmodium</i> falciparum)	Thai6 <sup>E252Q</sup>	T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA	NHP4076	
Strain, strain background ( <i>Plasmodium</i> falciparum)	Thai7 <sup>E252Q</sup>	T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA	NHP4673	
Strain, strain background ( <i>Escherichia coli</i> )	HST08	Takara	Cat. #636766	Stellar™ Competent Cells

Genetic reagent ( <i>Plasmodium</i> falciparum)	Transgenic parasite lines	This study and (Straimer <i>et al.</i> , 2015)	See Supplementary file 5	Available from D. Fidock upon request
Commercial assay or kit	In-Fusion® HD Cloning Plus kit	Takara	Cat. #638909	
Commercial assay or kit	QuantiFast Multiplex PCR Kit	Qiagen	Cat. #204654	
Sequence-based reagents	Oligonucleotides	This study	See Supplementary file 7	
Recombinant DNA reagents	Plasmids	This study	See Supplementary file 8	Available from D. Fidock upon request
Sequence-based reagents	qPCR primers and probes	This study	See Supplementary file 9	
Antibody	Anti-K13 ( <i>P. falciparum</i> ) (Mouse monoclonal)	I. Trakht, Columbia University Medical Center, New York, NY, USA (Gnadig <i>et al.</i> , 2020)		Antibody clone E9 WB (1:1000)
Antibody	Anti-ERD2 ( <i>P. falciparum</i> ) (Rabbit polyclonal)	MR4, BEI Resources	MRA-1	WB (1:1000)
Antibody	StarBright Blue 700 goat anti-mouse	Bio-Rad	12004158	WB (1:200)
Antibody	StarBright Blue 520 goat anti-rabbit	Bio-Rad	12005869	WB (1:1000)
Other	4–20% Criterion™ TGX™ Precast Protein Gel	Bio-Rad	5671093	Used with recommended buffers, also purchased from Bio-Rad
Chemical compound, drug	Carbenicillin disodium salt	Sigma	C1389	
Chemical compound, drug	WR99210	Jacobus Pharmaceuticals		
Chemical compound, drug	Dihydroartemisinin (DHA)	Sigma	D7439	

Software, algorithm	GraphPad Prism Version 9	GraphPad Software, San Diego, CA, USA	graphpad.com
Software, algorithm	ImageJ software	NIH, Bethesda, MD, USA	imagej.nih.gov

420

#### 421 Sample collection and *K13* genotyping

422 Samples were obtained as blood-spot filter papers from patients seeking treatment at sites involved in national 423 surveys of antimalarial drug resistance, or patients enrolled in therapeutic efficacy studies, or asymptomatic 424 participants enrolled in surveillance programs. Collection details from African and Cambodian samples are 425 provided in Figure 1-source data 1 and Figure 4-source data 1, respectively. Samples were processed at the 426 Pasteur Institute in Paris or the Pasteur Institute in Cambodia, as detailed in Supplementary file 1. These 427 investigators vouch for the accuracy and completeness of the molecular data. DNA was extracted from dried 428 blood spots using QIAmp Mini kits, as described (Menard et al., 2016). A nested PCR was performed on each 429 sample to amplify the K13-propeller domain, corresponding to codons 440-680. PCR products were sequenced 430 using internal primers and electropherograms analyzed on both strands, using the Pf3D7 1343700 3D7 431 sequence as the wild-type reference. Quality controls included adding six blinded quality-control samples to 432 each 96-well sequencing plate prepared from samples from each in-country partner and independently retesting 433 randomly selected blood samples. Isolates with mixed alleles were considered to be mutated for the purposes of 434 estimating the mutation frequencies.

435

#### 436 *P. falciparum* parasite *in vitro* culture

437 Plasmodium falciparum asexual blood-stage parasites were cultured in human erythrocytes at 3% hematocrit in 438 RPMI-1640 medium supplemented with 2 mM L-glutamine, 50 mg/L hypoxanthine, 25 mM HEPES, 0.21% 439 NaHCO3, 10 mg/L gentamycin and 0.5% w/v Albumax II (Invitrogen). Parasites were maintained at 37°C in 5% 440 O<sub>2</sub>, 5% CO<sub>2</sub>, and 90% N<sub>2</sub>. The geographic origin and year of culture adaptation for lines employed herein are 441 described in **Supplementary file 4**. Parasite lines were authenticated by genotyping resistance genes and were 442 screened by PCR for Mycoplasma every 3-6 months.

#### 444 Whole-genome sequencing of parental lines

445 To define the genome sequences of our *P. falciparum* lines used for transfection, we lysed parasites in 0.05% 446 saponin, washed them with 1×PBS, and purified genomic DNA (gDNA) using the QIAamp DNA Blood Midi Kit 447 (Qiagen). DNA concentrations were quantified by NanoDrop (Thermo Scientific) and Qubit (Invitrogen) prior to 448 sequencing. 200 ng of gDNA was used to prepare sequencing libraries using the Illumina Nextera DNA Flex 449 library prep kit with dual indices. Samples were multiplexed and sequenced on an Illumina MiSeq to obtain 300 450 bp paired-end reads at an average of 50× depth of coverage. Sequence reads were aligned to 451 the P. falciparum 3D7 reference genome (PlasmoDB version 36) using Burrow-Wheeler Alignment, PCR 452 duplicates and unmapped reads were filtered out using Samtools and Picard. Reads were realigned around 453 indels using GATK RealignerTargetCreator and base quality scores were recalibrated using GATK 454 BaseRecalibrator. GATK HaplotypeCaller (version 3.8) was used to identify all single nucleotide polymorphisms 455 (SNPs). These SNPs were filtered based on quality scores (variant quality as function of depth QD > 1.5, 456 mapping quality > 40, min base quality score > 18) and read depth (> 5) to obtain high-quality SNPs, which were 457 annotated using snpEFF. Integrated Genome Viewer was used to visually verify the presence of SNPs. BIC-Seq 458 was used to check for copy number variations using the Bayesian statistical model (Xi et al., 2011). Copy 459 number variations in highly polymorphic surface antigens and multi-gene families were removed as these are 460 prone to stochastic changes during in vitro culture.

461

Whole-genome sequencing data were used to determine the genotypes of the antimalarial drug resistance loci *pfcrt, mdr1, dhfr* and *dhps* (Haldar *et al.*, 2018). We also genotyped *fd, arps10, mdr2, ubp1,* and *ap-2µ*, which were previously associated with ART resistance (Henriques *et al.*, 2014; Miotto *et al.*, 2015; Cerqueira *et al.*, 2017; Adams *et al.*, 2018). These results are described in **Supplementary file 4.** 

466

#### 467 Cloning of *K13*, *fd* and *mdr2* plasmids

Zinc-finger nuclease-meditated editing of select mutations in the *K13* locus was performed as previously described (Straimer *et al.*, 2015). CRISPR/Cas9 editing of *K13* mutations was achieved using the pDC2-camcoSpCas9-U6-gRNA-h*dhfr* all-in-one plasmid that contains a *P. falciparum* codon-optimized Cas9 sequence, a human dihydrofolate reductase (h*dhfr*) gene expression cassette (conferring resistance to WR99210) and restriction enzyme insertion sites for the guide RNA (gRNA) and donor template (White *et al.*, 2019). A K13 473 propeller domain-specific gRNA was introduced into this vector at the BbsI restriction sites using the primer pair 474 p1+p2 (Supplementary file 7) using T4 DNA ligase (New England BioLabs). Oligos were phosphorylated and 475 annealed prior to cloning. A donor template consisting of a 1.5 kb region of the K13 coding region including the 476 entire propeller domain was amplified using the primer pair p3+p4 and cloned into the pGEM T-easy vector 477 system (Promega). This donor sequence was subjected to site-directed mutagenesis in the pGEM vector to 478 introduce silent shield mutations at the Cas9 cleavage site using the primer pair p5+p6, and to introduce allele-479 specific mutations using primer pairs (p7 to p20). K13 donor sequences were amplified from the pGEM vector 480 using the primer pair p21+p22 and sub-cloned into the pDC2-cam-coSpCas9-U6-gRNA-hdhfr plasmid at the 481 EcoRI and AatII restriction sites by In-Fusion Cloning (Takara). Final plasmids (see Supplementary file 8) were 482 sequenced using primers p23 to p25. A schematic showing the method of K13 plasmid construction can be 483 found in **Supplementary file 2**. Both our customized zinc-finger nuclease and CRISPR/Cas9 approaches 484 generated the desired amino acid substitutions without the genomic integration of any plasmid sequences or 485 any additional amino acid changes in the K13 locus, and thus provide fully comparable data.

486

487 CRISPR/Cas9 editing of fd and mdr2 was performed using a separate all-in-one plasmid, pDC2-cam-Cas9-U6-488 gRNA-hdhfr, generated prior to the development of the codon-optimized version used above for K13 (Lim et al., 489 2016). Cloning was performed as for K13, except for gRNA cloning that was performed using In-Fusion cloning 490 (Takara) rather than T4 ligase. Cloning of gRNAs was performed using primer pair p29+p30 for fd and p42+p43 491 for mdr2. Donor templates were amplified and cloned into the final vector using the primer pairs p31+p32 for fd 492 and p44+p45 for *mdr2*. Site-directed mutagenesis was performed using the allele-specific primer pairs p33+p34 493 or p35+p36 for fd, and p46+p47 or p48+p49 for mdr2. All final plasmids (for both fd and mdr2, see 494 Supplementary file 8) were sequenced using the primer pair p37+p38 (Supplementary file 7). Schematic 495 representations of final plasmids are shown in **Supplementary file 6**.

496

#### 497 Generation of K13, fd and mdr2 gene-edited parasite lines

Gene-edited lines were generated by electroporating ring-stage parasites at 5-10% parasitemia with 50 µg of purified circular plasmid DNA resuspended in Cytomix. Transfected parasites were selected by culturing in the presence of WR99210 (Jacobus Pharmaceuticals) for six days post electroporation. Parental lines harboring 2-3 mutations in the *P. falciparum* dihydrofolate reductase (*dhfr*) gene were exposed to 2.5 nM WR99210, while

502 parasites harboring four *dhfr* mutations were selected under 10 nM WR99210 (see Supplementary file 4 for *dhfr* genotypes of transfected lines). Parasite cultures were monitored for recrudescence by microscopy for up 503 504 six weeks post electroporation. To test for successful editing, the K13 locus was amplified directly from 505 parasitized whole blood using the primer pair p26+p27 (Supplementary file 7) and the MyTaq<sup>™</sup> Blood-PCR Kit 506 (Bioline). Primer pairs p39+p40 and p50+p51 were used to amplify fd and mdr2, respectively. PCR products were submitted for Sanger sequencing using the PCR primers as well as primer p28 in the case of K13, p41 (fd) 507 508 or p52 (mdr2). Bulk-transfected cultures showing evidence of editing by Sanger sequencing were cloned by 509 limiting dilution. All gene-edited transgenic lines generated herein are described in Supplementary file 5.

510

#### 511 Parasite synchronization, ring-stage survival assays (RSAs) and flow cytometry

512 Synchronized parasite cultures were obtained by exposing predominantly ring-stage cultures to 5% D-Sorbitol 513 (Sigma) for 15 min at 37°C to remove mature parasites. After 36 h of subsequent culture, multinucleated 514 schizonts were purified over a density gradient consisting of 75% Percoll (Sigma). Purified schizonts were 515 incubated with fresh RBCs for 3h, and early rings (0-3 hours post invasion; hpi) were treated with 5% D-Sorbitol 516 to remove remaining schizonts.

517

518 In vitro RSAs were conducted as previously described, with minor adaptations (Straimer et al., 2015). Briefly, 519 tightly synchronized 0-3 hpi rings were exposed to a pharmacologically-relevant dose of 700 nM DHA or 0.1% 520 dimethyl sulfoxide (DMSO; vehicle control) for 6 h at 1% parasitemia and 2% hematocrit, washed three times 521 with RPMI medium to remove drug, transferred to fresh 96-well plates, and cultured for an additional 66 h in 522 drug-free medium. Removal of media and resuspension of parasite cultures was performed on a Freedom Evo 523 100 liquid-handling instrument (Tecan). Parasitemias were measured at 72 h by flow cytometry (see below) with 524 at least 50,000 events captured per sample. Parasite survival was expressed as the percentage value of the 525 parasitemia in DHA-treated samples divided by the parasitemia in DMSO-treated samples processed in parallel. 526 We considered any RSA mean survival rates <2% to be ART sensitive.

527

Flow cytometry was performed on an BD Accuri<sup>™</sup> C6 Plus cytometer with a HyperCyt plate sampling
attachment (IntelliCyt), or on an iQue3® Screener Plus cytometer (Sartorius). Cells were stained with 1×SYBR
Green (ThermoFisher) and 100 nM MitoTracker DeepRed (ThermoFisher) for 30 min and diluted in 1×PBS prior

to sampling. Percent parasitemia was determined as the percentage of MitoTracker positive and SYBR Green positive cells. For RSAs, >50,000 events were captured per well.

533

#### 534 Western blot analysis of K13 expression levels in edited lines

535 Western blots were performed with lysates from tightly synchronized rings harvested 0-6 h post invasion. 536 Parasite cultures were washed twice in ice-cold 1× phosphate-buffered saline (PBS), and parasites isolated by 537 treatment with 0.05% saponin in PBS. Released parasites were lysed in 4% SDS, 0.5% Triton X-100 and 0.5% 538 PBS supplemented 1× protease inhibitors (Halt Protease Inhibitors Cocktail, ThermoFisher). Samples were 539 centrifuged at 14,000 rpm for 10 min to pellet cellular debris. Supernatants were collected and protein 540 concentrations were determined using the DC protein assay kit (Bio-Rad). Laemmli Sample Buffer (Bio-Rad) 541 was added to lysates and samples were denatured at 90°C for 10 min. Proteins were electrophoresed on precast 4-20% Tris-Glycine gels (Bio-Rad) and transferred onto nitrocellulose membranes. Western blots were 542 543 probed with a 1:1000 dilution of primary antibodies to K13 (Gnadig et al., 2020) or the loading control ERD2 544 (BEI Resources), followed by a 1:200 dilution of fluorescent StarBright secondary antibodies (Bio-Rad). Western 545 blots were imaged on a ChemiDoc system (Bio-Rad) and band intensities quantified using ImageJ.

546

#### 547 TaqMan allelic discrimination real-time (quantitative) PCR-based fitness assays

548 Fitness assays with African K13-edited parasite lines were performed by co-culturing isogenic wild-type 549 unedited and mutant edited parasites in 1:1 ratios. Assays were initiated with tightly synchronized trophozoites. 550 Final culture volumes were 3 mL. Cultures were maintained in 12-well plates and monitored every four days 551 over a period of 36 days (18 generations) by harvesting at each time point a fraction of each co-culture for 552 saponin lysis. gDNA was then extracted using the QIAamp DNA Blood Mini Kit (Qiagen). The percentage of the 553 wild-type or mutant allele in each sample was determined in TagMan allelic discrimination real-time PCR assays. TagMan primers (forward and reverse) and TagMan fluorescence-labeled minor groove binder probes 554 555 (FAM or HEX, Eurofins) are described in Supplementary file 9. Probes were designed to specifically detect the 556 K13 R561H, M579I or C580Y propeller mutations. The efficiency and sensitivity of the TagMan primers was 557 assessed using standard curves comprising 10-fold serially diluted templates ranging from 10 ng to 0.001 ng. Robustness was demonstrated by high efficiency (88-95%) and R<sup>2</sup> values (0.98-1.00). The quantitative accuracy 558 559 in genotype calling was assessed by performing multiplex qPCR assays using mixtures of wild-type and mutant plasmids in fixed ratios (0:100, 20:80, 40:60, 50:50, 60:40, 80:20, 100:0). Triplicate data points clustered tightly, indicating high reproducibility in the data across the fitted curve ( $R^2 = 0.89$  to 0.91).

562

563 Purified gDNA from fitness co-cultures was subsequently amplified and labeled using the primers and probes 564 described in Supplementary file 9. gPCR reactions for each sample were run in triplicate. 20 µL reactions consisted of 1×QuantiFAST reaction mix containing ROX reference dye (Qiagen), 0.66 µM of forward and 565 566 reverse primers, 0.16 µM FAM-MGB and HEX-MGB TagMan probes, and 10 ng genomic DNA. Amplification 567 and detection of fluorescence were carried out on a QuantStudio 3 gPCR machine (Applied Biosystems) using the genotyping assay mode. Cycling conditions were as follows: 30s at 60°C; 5 min at 95°C; and 40 cycles of 568 569 30s at 95°C and 1 min at 60°C for primer annealing and extension. Every assay was run with positive controls 570 (wild-type or mutant plasmids at different fixed ratios). No-template negative controls (water) in triplicates were 571 processed in parallel. Rn, the fluorescence of the FAM or HEX probe, was normalized to the fluorescence signal 572 of the ROX reporter dye. Background-normalized fluorescence (Rn minus baseline, or ΔRn) was calculated as a 573 function of cycle number.

574

To determine the wild-type or mutant allele frequency in each sample, we first confirmed the presence of the allele by only retaining values where the threshold cycle ( $C_t$ ) of the sample was less than the no-template control by at least three cycles. Next, we subtracted the  $\Delta Rn$  of the samples from the background  $\Delta Rn$  of the notemplate negative control. We subsequently normalized the fluorescence to 100% using the positive control plasmids to obtain the percentage of the wild-type and mutant alleles for each sample. The final percentage of the mutant allele was defined as the average of these two values: the normalized percentage of the mutant allele, and 100% minus the normalized percentage of the wild-type allele.

582

#### 583 eGFP-based fitness assays

Fitness assays with Dd2,  $RF7^{C580Y}$  and Cam3.II parasite lines were performed using mixed culture competition assays with an eGFP-positive (eGFP<sup>+</sup>) Dd2 reporter line (Ross *et al.*, 2018). This reporter line uses a *calmodulin* promoter sequence to express high levels of GFP and includes human *dhfr* and *blasticidin S-deaminase* expression cassettes. This line was earlier reported to have a reduced rate of growth relative to parental nonrecombinant Dd2, presumably at least in part because of its high levels of GFP expression (Ross *et al.*, 2018; 589 Dhingra *et al.*, 2019). With our Dd2 parasites, *K13*-edited lines were co-cultured in 1:1 ratios with the reporter 590 line. This ratio was adjusted to 10:1 or 100:1 for *fd*-edited RF7<sup>C580Y</sup> and *mdr2*-edited Cam3.II parasites relative to 591 the eGFP line, given the slower rate of growth with RF7<sup>C580Y</sup> and Cam3.II. Fitness assays were initiated with 592 tightly synchronized trophozoites in 96-well plates, with 200  $\mu$ L culture volumes. Percentages of eGFP<sup>+</sup> 593 parasites were monitored by flow cytometry every two days over a period of 20 days (10 generations). Flow 594 cytometry was performed as written above, except that only 100 nM MitoTracker DeepRed staining was used to 595 detect total parasitemias, since SYBR Green and eGFP fluoresce in the same channel.

596

#### 597 Fitness Costs

598 The fitness cost associated with a line expressing a given K13 mutation was calculated was calculated relative 599 to its isogenic wild-type counterpart using the following equation:

 $P' = P((1 - x)^n)$ 

where P' is equal to the parasitemia at the assay endpoint, P is equal to the parasitemia on day 0, n is equal to the number of generations from the assay start to finish, and x is equal to the fitness cost. This equation assumes 100% growth for the wild-type comparator line. For qPCR and GFP-based fitness assays, days 36 and 20 were set as the assay endpoints, resulting in the number of parasite generations (n) being set to 18 and 10, respectively.

605

#### 606 Ethics statement

Health care facilities were in charge of collecting anonymized *P. falciparum* positive cases. Identification of individuals cannot be established. The studies were approved by ethics committees listed in **Supplementary file 1**. We note that the sponsors had no role in the study design or in the collection or analysis of the data. There was no confidentiality agreement between the sponsors and the investigators.

611

### 612 Acknowledgments

613 We thank Dr. Pascal Ringwald (World Health Organization) for his support and feedback. DAF gratefully 614 acknowledges the US National Institutes of Health (R01 AI109023), the Department of Defense 615 (W81XWH1910086) and the Bill & Melinda Gates Foundation (OPP1201387) for their financial support. BHS 616 was funded in part by T32 Al106711 (PD: D. Fidock). SM is a recipient of a Human Frontiers of Science Program Long-Term Fellowship. CHC was supported in part by the NIH (R01 Al121558; PI: Jonathan Juliano). 617 618 FN is supported by the Wellcome Trust of Great Britain (Grant ID: 106698). TJCA acknowledges funding 619 support from the NIH (R37 AI048071). DAF and DM gratefully acknowledge the World Health Organization for 620 their funding. We thank the following individuals for their kind help with the K13-genotyped samples - Chad: Ali 621 S. Djiddi, Mahamat S. I. Diar, Kodbessé Boulotigam, Mbanga Djimadoum, Hamit M. Alio, Mahamat M. H. 622 Taisso, Issa A. Haggar; Burkina Faso: TES 2017-2018 team and the US President's Malaria Initiative through 623 the Improving Malaria Care Project as the funding agency for the study in Burkina Faso, Chris-Boris G. Panté-624 Wockama; Burundi: Dismas Baza; Tanzania: Mwaka Kakolwa, Celine Mandara, Tanzania TES coordination 625 team for the Ministry of Health; Sierra Leone: Anitta R. Y. Kamara, Foday Sahr, Mohamed Samai; The Gambia: 626 Balla Kandeh, Joseph Okebe, Serign J. Ceesay, Baboucarr Babou, Emily Jagne, Alsan Jobe; Congo: Brice S. 627 Pembet, Jean M. Youndouka; Somalia: Jamal Ghilan Hefzullah Amran, Abdillahi Mohamed Hassan, Abdikarim 628 Hussein Hassan and Ali Abdulrahman; Rwanda: extended TES team for the Malaria and Other Parasitic 629 Diseases Division, Rwanda Biomedical Centre.

630

## 631 Competing interests

632 MW is a former staff member of the World Health Organization. MW alone is responsible for the views 633 expressed in this publication, which do not necessarily represent the decisions, policies or views of the World 634 Health Organization. The other authors declare that no competing interests exist.

# 635 **References**

- Adams T, Ennuson NAA, Quashie NB, Futagbi G, Matrevi S, Hagan OCK, Abuaku B, Koram KA, Duah NO.
  2018. Prevalence of *Plasmodium falciparum* delayed clearance associated polymorphisms in adaptor
  protein complex 2 mu subunit (*pfap2mu*) and ubiquitin specific protease 1 (*pfubp1*) genes in Ghanaian
  isolates. *Parasit Vectors* 11:175. DOI: https://doi.org/10.1186/s13071-018-2762-3. PMID: 29530100
- Amambua-Ngwa A, Amenga-Etego L, Kamau E, Amato R, Ghansah A, Golassa L, Randrianarivelojosia M, Ishengoma D, Apinjoh T, Maiga-Ascofare O, Andagalu B, Yavo W, Bouyou-Akotet M, Kolapo O, Mane K, Worwui A, Jeffries D, Simpson V, D'Alessandro U, Kwiatkowski D, Djimde AA. 2019. Major subpopulations of *Plasmodium falciparum* in sub-Saharan Africa. *Science* 365:813-816. DOI: <u>https://doi.org/10.1126/science.aav5427</u>. PMID: 31439796
- Amato R, Pearson RD, Almagro-Garcia J, Amaratunga C, Lim P, Suon S, Sreng S, Drury E, Stalker J, Miotto O,
  Fairhurst RM, Kwiatkowski DP. 2018. Origins of the current outbreak of multidrug-resistant malaria in
  southeast Asia: a retrospective genetic study. *Lancet Infect Dis* 18:337-345. DOI:
  <a href="https://doi.org/10.1016/S1473-3099(18)30068-9">https://doi.org/10.1016/S1473-3099(18)30068-9</a>. PMID: 29398391
- Anderson TJ, Nair S, McDew-White M, Cheeseman IH, Nkhoma S, Bilgic F, McGready R, Ashley E, Pyae Phyo
  A, White NJ, Nosten F. 2017. Population parameters underlying an ongoing soft sweep in Southeast
  Asian malaria parasites. *Mol Biol Evol* 34:131-144. DOI: <u>https://doi.org/10.1093/molbev/msw228</u>. PMID:
  28025270
- Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature* 505:50-55. DOI: <u>https://doi.org/10.1038/nature12876</u>. PMID: 24352242
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, 658 Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, 659 Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, 660 661 Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, 662 663 Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad 664 R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, 665 666 Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, 667 Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ, Tracking Resistance to Artemisinin Consortium. 2014. Spread of artemisinin resistance in Plasmodium 668 falciparum malaria, N Engl J Med 371:411-423, DOI: https://doi.org/10.1056/NEJMoa1314981, PMID: 669 670 25075834
- Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E, Tumwebaze P, Chin DM, Cooper RA, Yeka
  A, Kamya MR, Dorsey G, Nsobya SL, Bailey J, Rosenthal PJ. 2020. Changing prevalence of potential
  mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. *J Infect Dis* 223:985994. DOI: <u>https://doi.org/10.1093/infdis/jiaa687</u>. PMID: 33146722
- Bergmann C, van Loon W, Habarugira F, Tacoli C, Jager JC, Savelsberg D, Nshimiyimana F, Rwamugema E,
  Mbarushimana D, Ndoli J, Sendegeya A, Bayingana C, Mockenhaupt FP. 2021. Increase in Kelch 13
  polymorphisms in *Plasmodium falciparum*, Southern Rwanda. *Emerg Infect Dis* 27:294-296. DOI:
  <u>https://doi.org/10.3201/eid2701.203527</u>. PMID: 33350925
- Birnbaum J, Flemming S, Reichard N, Soares AB, Mesen-Ramirez P, Jonscher E, Bergmann B, Spielmann T.
  2017. A genetic system to study *Plasmodium falciparum* protein function. *Nat Methods* 14:450-456.
  DOI: <u>https://doi.org/10.1038/nmeth.4223</u>. PMID: 28288121
- Birnbaum J, Scharf S, Schmidt S, Jonscher E, Hoeijmakers WAM, Flemming S, Toenhake CG, Schmitt M, Sabitzki R, Bergmann B, Frohlke U, Mesen-Ramirez P, Blancke Soares A, Herrmann H, Bartfai R, Spielmann T. 2020. A Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites. *Science* 367:51-59. DOI: <u>https://doi.org/10.1126/science.aax4735</u>. PMID: 31896710
- Cerqueira GC, Cheeseman IH, Schaffner SF, Nair S, McDew-White M, Phyo AP, Ashley EA, Melnikov A, Rogov
   P, Birren BW, Nosten F, Anderson TJC, Neafsey DE. 2017. Longitudinal genomic surveillance of
   *Plasmodium falciparum* malaria parasites reveals complex genomic architecture of emerging artemisinin
   resistance. *Genome Biol* 18:78. DOI: <a href="https://doi.org/10.1186/s13059-017-1204-4">https://doi.org/10.1186/s13059-017-1204-4</a>. PMID: 28454557

- 690 Conrad MD, Rosenthal PJ. 2019. Antimalarial drug resistance in Africa: the calm before the storm? *Lancet Infect* 691 *Dis* 19:e338-e351. DOI: <u>https://doi.org/10.1016/S1473-3099(19)30261-0</u>. PMID: 31375467
- Das S, Manna S, Saha B, Hati AK, Roy S. 2019. Novel *pfkelch13* gene polymorphism associates with artemisinin resistance in Eastern India. *Clin Infect Dis* 69:1144-1152. DOI: <a href="https://doi.org/10.1093/cid/ciy1038">https://doi.org/10.1093/cid/ciy1038</a>. PMID: 30535043
- Demas AR, Sharma AI, Wong W, Early AM, Redmond S, Bopp S, Neafsey DE, Volkman SK, Hartl DL, Wirth DF. 2018. Mutations in *Plasmodium falciparum* actin-binding protein coronin confer reduced artemisinin susceptibility. *Proc Natl Acad Sci USA* 115:12799-12804. DOI: https://doi.org/10.1073/pnas.1812317115. PMID: 30420498
- Dhingra SK, Small-Saunders JL, Menard D, Fidock DA. 2019. *Plasmodium falciparum* resistance to piperaquine
   driven by PfCRT. *Lancet Infect Dis* 19:1168-1169. DOI: <u>https://doi.org/10.1016/S1473-3099(19)30543-</u>
   2. PMID: 31657776
- Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ,
   Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon
   P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 361:455-467. DOI: <a href="https://doi.org/10.1056/NEJMoa0808859">https://doi.org/10.1056/NEJMoa0808859</a>. PMID: 19641202
- Eastman RT, Fidock DA. 2009. Artemisinin-based combination therapies: a vital tool in efforts to eliminate
   malaria. *Nat Rev Microbiol* 7:864-874. DOI: <u>https://doi.org/10.1038/nrmicro2239</u>. PMID: 19881520
- Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, Claassen CW, Dzinjalamala FK, Plowe
   CV. 2014. Return of widespread chloroquine-sensitive *Plasmodium falciparum* to Malawi. *J Infect Dis* 210:1110-1114. DOI: https://doi.org/10.1093/infdis/jiu216. PMID: 24723474
- Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, Lopez-Rubio JJ. 2014. Genome editing in the human malaria parasite *Plasmodium falciparum* using the CRISPR-Cas9 system. *Nat Biotechnol* 32:819-821. DOI: <u>https://doi.org/10.1038/nbt.2925</u>. PMID: 24880488
- Gnadig NF, Stokes BH, Edwards RL, Kalantarov GF, Heimsch KC, Kuderjavy M, Crane A, Lee MCS, Straimer
  J, Becker K, Trakht IN, Odom John AR, Mok S, Fidock DA. 2020. Insights into the intracellular
  localization, protein associations and artemisinin resistance properties of *Plasmodium falciparum* K13. *PLoS Pathog* 16:e1008482. DOI: <a href="https://doi.org/10.1371/journal.ppat.1008482">https://doi.org/10.1371/journal.ppat.1008482</a>. PMID: 32310999
- WWARN K13 Genotype-Phenotype Study Group. 2019. Association of mutations in the *Plasmodium falciparum* Kelch13 gene (Pf3D7\_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. *BMC Med* 17:1. DOI: <u>https://doi.org/10.1186/s12916-</u> 018-1207-3. PMID: 30651111
- Haldar K, Bhattacharjee S, Safeukui I. 2018. Drug resistance in *Plasmodium. Nat Rev Microbiol* 16:156-170.
   DOI: <a href="https://doi.org/10.1038/nrmicro.2017.161">https://doi.org/10.1038/nrmicro.2017.161</a>. PMID: 29355852
- Hanboonkunupakarn B, White NJ. 2020. Advances and roadblocks in the treatment of malaria. *Br J Clin Pharmacol* Jul 12. DOI: <u>https://doi.org/10.1111/bcp.14474</u>. PMID: 32656850
- Henrici RC, van Schalkwyk DA, Sutherland CJ. 2019. Modification of *pfap2mu* and *pfubp1* markedly reduces
   ring-stage susceptibility of *Plasmodium falciparum* to artemisinin *in vitro*. *Antimicrob Agents Chemother* 64. DOI: <u>https://doi.org/10.1128/AAC.01542-19</u>. PMID: 31636063
- Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, van Schalkwyk DA, Sawa P, Omar
  SA, Clark TG, Bousema T, Sutherland CJ. 2014. Directional selection at the *pfmdr1*, *pfcrt*, *pfubp1*, and *pfap2mu* loci of *Plasmodium falciparum* in Kenyan children treated with ACT. *J Infect Dis* 210:20012008. DOI: <a href="https://doi.org/10.1093/infdis/jiu358">https://doi.org/10.1093/infdis/jiu358</a>. PMID: 24994911
- 733 Imwong M, Dhorda M, Myo Tun K, Thu AM, Phyo AP, Proux S, Suwannasin K, Kunasol C, Srisutham S, 734 Duanguppama J, Vongpromek R, Promnarate C, Saejeng A, Khantikul N, Sugaram R, Thanapongpichat S, Sawangjaroen N, Sutawong K, Han KT, Htut Y, Linn K, Win AA, Hlaing TM, van 735 736 der Pluijm RW, Mayxay M, Pongvongsa T, Phommasone K, Tripura R, Peto TJ, von Seidlein L, Nguon 737 C, Lek D, Chan XHS, Rekol H, Leang R, Huch C, Kwiatkowski DP, Miotto O, Ashley EA, Kyaw MP, 738 Pukrittayakamee S, Day NPJ, Dondorp AM, Smithuis FM, Nosten FH, White NJ. 2020. Molecular 739 epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infect Dis 20:1470-1480. DOI: https://doi.org/10.1016/S1473-3099(20)30228-0. PMID: 740 741 32679084
- Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, Smithuis FM, Hlaing TM, Tun KM, van der Pluijm RW, Tripura R, Miotto O, Menard D, Dhorda M, Day NPJ, White NJ, Dondorp AM. 2017. The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater Mekong subregion: a molecular epidemiology observational study. *Lancet Infect Dis* **17**:491-497. DOI: <u>https://doi.org/10.1016/S1473-3099(17)30048-8</u>. PMID: 28161569

- Kayiba NK, Yobi DM, Tshibangu-Kabamba E, Tuan VP, Yamaoka Y, Devleesschauwer B, Mvumbi DM, Okitolonda Wemakoy E, De Mol P, Mvumbi GL, Hayette MP, Rosas-Aguirre A, Speybroeck N. 2020.
  Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging *Plasmodium falciparum* resistance to artemisinin: a systematic review. *Lancet Infect Dis* 21:e82-e92.
  DOI: <u>https://doi.org/10.1016/S1473-3099(20)30493-X</u>. PMID: 33125913
- Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE,
  Plowe CV. 2003. Reemergence of chloroquine-sensitive *Plasmodium falciparum* malaria after cessation
  of chloroquine use in Malawi. *J Infect Dis* 187:1870-1875. DOI: <a href="https://doi.org/10.1086/375419">https://doi.org/10.1086/375419</a>. PMID:
  12792863
- Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV. 2006.
   Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355:1959-1966. DOI: <a href="https://doi.org/10.1056/NEJMoa062032">https://doi.org/10.1056/NEJMoa062032</a>. PMID: 17093247
- Lim MY, LaMonte G, Lee MCS, Reimer C, Tan BH, Corey V, Tjahjadi BF, Chua A, Nachon M, Wintjens R, Gedeck P, Malleret B, Renia L, Bonamy GMC, Ho PC, Yeung BKS, Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA, Bifani P. 2016. UDP-galactose and acetyl-CoA transporters as *Plasmodium* multidrug resistance genes. *Nat Microbiol* 1:16166. DOI: <u>https://doi.org/10.1038/nmicrobiol.2016.166</u>.
  PMID: 27642791
- Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, Zhu G, Tang J, Liu Y, Wang W, Cao Y, Xu
   S, Gu Y, Li J, Zhang C, Gao Q, Menard D, Pain A, Yang H, Zhang Q, Cao J. 2017. Emergence of
   indigenous artemisinin-resistant *Plasmodium falciparum* in Africa. *N Engl J Med* 376:991-993. DOI:
   https://doi.org/10.1056/NEJMc1612765. PMID: 28225668
- MalariaGEN *Plasmodium falciparum* Community Project. 2016. Genomic epidemiology of artemisinin resistant malaria. *eLife* 5:e08714. DOI: <u>https://doi.org/10.7554/eLife.08714</u>. PMID: 26943619
- Mathieu LC, Cox H, Early AM, Mok S, Lazrek Y, Paquet JC, Ade MP, Lucchi NW, Grant Q, Udhayakumar V, Alexandre JS, Demar M, Ringwald P, Neafsey DE, Fidock DA, Musset L. 2020. Local emergence in Amazonia of *Plasmodium falciparum* k13 C580Y mutants associated with *in vitro* artemisinin resistance.
   *eLife* 9:e51015. DOI: <u>https://doi.org/10.7554/eLife.51015</u>. PMID: 32394893
- 774 Menard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, Rahim-Awab G, Barnadas C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH, Collet L, Cui L, Thakur GD, Dieye A, Djalle D, Dorkenoo MA, 775 Eboumbou-Moukoko CE, Espino FE, Fandeur T, Ferreira-da-Cruz MF, Fola AA, Fuehrer HP, Hassan 776 777 AM, Herrera S, Hongvanthong B, Houze S, Ibrahim ML, Jahirul-Karim M, Jiang L, Kano S, Ali-Khan W, 778 Khanthavong M, Kremsner PG, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Mazarati JB, Menard S, 779 Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niare K, Noedl H, Ouedraogo 780 JB, Pillai DR, Pradines B, Quang-Phuc B, Ramharter M, Randrianarivelojosia M, Sattabongkot J, Sheikh-Omar A, Silue KD, Sirima SB, Sutherland C, Syafruddin D, Tahar R, Tang LH, Toure OA, 781 782 Tshibangu-wa-Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, 783 Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale JC, Stokes B, Straimer J, 784 Witkowski B, Fidock DA, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O, Karma Consortium. 2016. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med 785 374:2453-2464. DOI: https://doi.org/10.1056/NEJMoa1513137. PMID: 27332904 786
- 787 Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, Lim P, Mead D, Oyola SO, 788 Dhorda M, Imwong M, Woodrow C, Manske M, Stalker J, Drury E, Campino S, Amenga-Etego L, Thanh 789 TN, Tran HT, Ringwald P, Bethell D, Nosten F, Phyo AP, Pukrittayakamee S, Chotivanich K, Chuor CM, 790 Nguon C, Suon S, Sreng S, Newton PN, Mayxay M, Khanthavong M, Hongvanthong B, Htut Y, Han KT, 791 Kyaw MP, Faiz MA, Fanello CI, Onyamboko M, Mokuolu OA, Jacob CG, Takala-Harrison S, Plowe CV, Day NP, Dondorp AM, Spencer CC, McVean G, Fairhurst RM, White NJ, Kwiatkowski DP. 2015. 792 793 Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet 47:226-234. DOI: 794 https://doi.org/10.1038/ng.3189. PMID: 25599401
- Miotto O, Sekihara M, Tachibana SI, Yamauchi M, Pearson RD, Amato R, Goncalves S, Mehra S, Noviyanti R, Marfurt J, Auburn S, Price RN, Mueller I, Ikeda M, Mori T, Hirai M, Tavul L, Hetzel MW, Laman M, Barry AE, Ringwald P, Ohashi J, Hombhanje F, Kwiatkowski DP, Mita T. 2020. Emergence of artemisininresistant *Plasmodium falciparum* with *kelch13* C580Y mutations on the island of New Guinea. *PLoS Pathog* 16:e1009133. DOI: https://doi.org/10.1371/journal.ppat.1009133. PMID: 33320907
- Mok S, Stokes BH, Gnadig NF, Ross LS, Yeo T, Amaratunga C, Allman E, Solyakov L, Bottrill AR, Tripathi J, Fairhurst RM, Llinas M, Bozdech Z, Tobin AB, Fidock DA. 2021. Artemisinin-resistant K13 mutations rewire *Plasmodium falciparum*'s intra-erythrocytic metabolic program to enhance survival. *Nat Commun* 12:530. DOI: <u>https://doi.org/10.1038/s41467-020-20805-w</u>. PMID: 33483501

- Nair S, Li X, Arya GA, McDew-White M, Ferrari M, Nosten F, Anderson TJC. 2018. Do fitness costs explain the
   rapid spread of *kelch13*-C580Y substitutions conferring artemisinin resistance? *Antimicrob Agents Chemother* 62:e00605-00618. DOI: https://doi.org/10.1128/AAC.00605-18. PMID: 29914963
- Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 (ARC1)
   Study Consortium. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med* 359:2619-2620. DOI: <u>https://doi.org/10.1056/NEJMc0805011</u>. PMID: 19064625
- Noedl H, Socheat D, Satimai W. 2009. Artemisinin-resistant malaria in Asia. N Engl J Med 361:540-541. DOI: <a href="https://doi.org/10.1056/NEJMc0900231">https://doi.org/10.1056/NEJMc0900231</a>. PMID: 19641219
- Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, Targett G, Drakeley CJ, Sutherland CJ. 2007. Seasonal carriage of *pfcrt* and *pfmdr1* alleles in Gambian *Plasmodium falciparum* imply reduced fitness of chloroquine-resistant parasites. *J Infect Dis* **196**:1613-1619. DOI: <u>https://doi.org/10.1086/522154</u>. PMID: 18008244
- Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, Nair S, White MM, Dziekan J, Ling C,
  Proux S, Konghahong K, Jeeyapant A, Woodrow CJ, Imwong M, McGready R, Lwin KM, Day NPJ,
  White NJ, Nosten F. 2016. Declining efficacy of artemisinin combination therapy against *P. falciparum*malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors. *Clin Infect Dis*63:784-791. DOI: <u>https://doi.org/10.1093/cid/ciw388</u>. PMID: 27313266
- Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kumpornsin K, Takala-Harrison S, Witkowski B, Fairhurst RM,
   Ariey F, Menard D, Fidock DA. 2018. Emerging Southeast Asian PfCRT mutations confer *Plasmodium falciparum* resistance to the first-line antimalarial piperaquine. *Nat Commun* 9:3314. DOI:
   <a href="https://doi.org/10.1038/s41467-018-05652-0">https://doi.org/10.1038/s41467-018-05652-0</a>. PMID: 30115924
- Schmedes SE, Patel D, Dhal S, Kelley J, Svigel SS, Dimbu PR, Adeothy AL, Kahunu GM, Nkoli PM, Beavogui AH, Kariuki S, Mathanga DP, Koita O, Ishengoma D, Mohamad A, Hawela M, Moriarty LF, Samuels AM, Gutman J, Plucinski MM, Udhayakumar V, Zhou Z, Lucchi NW, Venkatesan M, Halsey ES, Talundzic E.
  2021. *Plasmodium falciparum kelch 13* Mutations, 9 Countries in Africa, 2014-2018. *Emerg Infect Dis* 27:1902-1908. DOI: https://doi.org/10.3201/eid2707.203230. PMID: 34152946
- Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P, Ali F, Mohammad AB, Uhomoibhi
  P, Maikore I, Ogbulafor N, Nikau J, Kont MD, Challenger JD, Verity R, Lambert B, Cairns M, Rao B,
  Baguelin M, Whittles LK, Lees JA, Bhatia S, Knock ES, Okell L, Slater HC, Ghani AC, Walker PGT,
  Okoko OO, Churcher TS. 2020. The potential public health consequences of COVID-19 on malaria in
  Africa. *Nat Med* 26:1411-1416. DOI: <a href="https://doi.org/10.1038/s41591-020-1025-y">https://doi.org/10.1038/s41591-020-1025-y</a>. PMID: 32770167
- Siddiqui FA, Boonhok R, Cabrera M, Mbenda HGN, Wang M, Min H, Liang X, Qin J, Zhu X, Miao J, Cao Y, Cui
  L. 2020. Role of *Plasmodium falciparum* Kelch 13 protein mutations in *P. falciparum* populations from northeastern Myanmar in mediating artemisinin resistance. *mBio* 11:e01134-01119. DOI: <a href="https://doi.org/10.1128/mBio.01134-19">https://doi.org/10.1128/mBio.01134-19</a>. PMID: 32098812
- Siddiqui G, Srivastava A, Russell AS, Creek DJ. 2017. Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin-resistant *Plasmodium falciparum*. *J Infect Dis* 215:1435-1444. DOI: <u>https://doi.org/10.1093/infdis/jix156</u>. PMID: 28368494
- Straimer J, Gnadig NF, Stokes BH, Ehrenberger M, Crane AA, Fidock DA. 2017. *Plasmodium falciparum* K13
   mutations differentially impact ozonide susceptibility and parasite fitness *in vitro*. *mBio* 8:e00172-00117.
   DOI: <u>https://doi.org/10.1128/mBio.00172-17</u>. PMID: 28400526
- Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N, Zhang L, Lam
  S, Gregory PD, Urnov FD, Mercereau-Puijalon O, Benoit-Vical F, Fairhurst RM, Menard D, Fidock DA.
  2015. K13-propeller mutations confer artemisinin resistance in *Plasmodium falciparum* clinical isolates. *Science* 347:428-431. DOI: <a href="https://doi.org/10.1126/science.1260867">https://doi.org/10.1126/science.1260867</a>. PMID: 25502314
- Sutherland CJ, Henrici RC, Artavanis-Tsakonas K. 2020. Artemisinin susceptibility in the malaria parasite
   *Plasmodium falciparum*: propellers, adaptor proteins and the need for cellular healing. *FEMS Microbiol Rev.* DOI: <u>https://doi.org/10.1093/femsre/fuaa056</u>. PMID: 33095255
- Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, Ngamije D, Munyaneza T, Mazarati JB, Munguti K, Campagne P, Criscuolo A, Ariey F, Murindahabi M, Ringwald P, Fidock DA, Mbituyumuremyi A, Menard D. 2020. Emergence and clonal expansion of *in vitro* artemisinin-resistant *Plasmodium falciparum kelch13* R561H mutant parasites in Rwanda. *Nature Med* 26:1602-1608. DOI: <a href="https://doi.org/10.1038/s41591-020-1005-2">https://doi.org/10.1038/s41591-020-1005-2</a>. PMID: 32747827
- Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, Habimana RM, Rucogoza A, Moriarty
  LF, Sandford R, Piercefield E, Goldman I, Ezema B, Talundzic E, Pacheco MA, Escalante AA, Ngamije
  D, Mangala JN, Kabera M, Munguti K, Murindahabi M, Brieger W, Musanabaganwa C, Mutesa L,
  Udhayakumar V, Mbituyumuremyi A, Halsey ES, Lucchi NW. 2021. Association of *Plasmodium*

- *falciparum kelch13* R561H genotypes with delayed parasite clearance in Rwanda: an open-label, singlearm, multicentre, therapeutic efficacy study. *Lancet Infect Dis.* DOI: <u>https://doi.org/10.1016/S1473-</u>
   <u>3099(21)00142-0</u>. PMID: 33864801
- 864 van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, Jittamala P, 865 Hanboonkunupakarn B, Chutasmit K, Saelow C, Runjarern R, Kaewmok W, Tripura R, Peto TJ, Yok S, Suon S, Sreng S, Mao S, Oun S, Yen S, Amaratunga C, Lek D, Huy R, Dhorda M, Chotivanich K, Ashley EA, Mukaka M, Waithira N, Cheah PY, Maude RJ, Amato R, Pearson RD, Goncalves S, Jacob 866 867 868 CG, Hamilton WL, Fairhurst RM, Tarning J, Winterberg M, Kwiatkowski DP, Pukrittayakamee S, Hien 869 TT, Day NP, Miotto O, White NJ, Dondorp AM, 2019, Determinants of dihydroartemisinin-piperaguine 870 treatment failure in *Plasmodium falciparum* malaria in Cambodia, Thailand, and Vietnam: a prospective pharmacological. 871 and genetic study. Lancet Infect Dis **19**:952-961. DOI: clinical. 872 https://doi.org/10.1016/S1473-3099(19)30391-3. PMID: 31345710
- Vaughan AM, Pinapati RS, Cheeseman IH, Camargo N, Fishbaugher M, Checkley LA, Nair S, Hutyra CA,
  Nosten FH, Anderson TJ, Ferdig MT, Kappe SH. 2015. *Plasmodium falciparum* genetic crosses in a
  humanized mouse model. *Nat Methods* 12:631-633. DOI: <u>https://doi.org/10.1038/nmeth.3432</u>. PMID:
  26030447
- 877 White J, Dhingra SK, Deng X, El Mazouni F, Lee MCS, Afanador GA, Lawong A, Tomchick DR, Ng CL, Bath J, 878 Rathod PK, Fidock DA, Phillips MA. 2019. Identification and mechanistic understanding of 879 dihydroorotate dehydrogenase point mutations in *Plasmodium falciparum* that confer in vitro resistance 880 the clinical candidate DSM265. ACS Infect Dis **5**:90-101. DOI: to 881 https://doi.org/10.1021/acsinfecdis.8b00211. PMID: 30375858
- White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. 2014. Malaria. *Lancet* 383:723-735. DOI: <u>https://doi.org/10.1016/S0140-6736(13)60024-0</u>. PMID: 23953767
- WHO. 2019. WHO status report on artemisinin resistance and ACT efficacy. <u>https://www.who.int/docs/default-source/documents/publications/gmp/who-cds-gmp-2019-17-eng.pdf?ua=1</u>.
- WHO. 2020. World malaria report 2020. <u>https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020</u>.
- Wicht KJ, Mok S, Fidock DA. 2020. Molecular mechanisms of drug resistance in *Plasmodium falciparum* malaria. *Annu Rev Microbiol* **74**:431-454. DOI: <u>https://doi.org/10.1146/annurev-micro-020518-115546</u>.
   PMID: 32905757
- Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B, Anderson JM,
  Duong S, Chuor CM, Taylor WR, Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D. 2013. Novel
  phenotypic assays for the detection of artemisinin-resistant *Plasmodium falciparum* malaria in
  Cambodia: *in-vitro* and *ex-vivo* drug-response studies. *Lancet Infect Dis* 13:1043-1049. DOI:
  <u>https://doi.org/10.1016/S1473-3099(13)70252-4</u>. PMID: 24035558
- Witkowski B, Lelievre J, Barragan MJ, Laurent V, Su XZ, Berry A, Benoit-Vical F. 2010. Increased tolerance to artemisinin in *Plasmodium falciparum* is mediated by a quiescence mechanism. *Antimicrob Agents Chemother* 54:1872-1877. DOI: <u>https://doi.org/10.1128/AAC.01636-09</u>. PMID: 20160056
- Witmer K, Dahalan FA, Delves MJ, Yahiya S, Watson OJ, Straschil U, Chiwcharoen D, Sornboon B, Pukrittayakamee S, Pearson RD, Howick VM, Lawniczak MKN, White NJ, Dondorp AM, Okell LC, Chotivanich K, Ruecker A, Baum J. 2020. Transmission of artemisinin-resistant malaria parasites to mosquitoes under antimalarial drug pressure. *Antimicrob Agents Chemother* 65. DOI: <u>https://doi.org/10.1128/AAC.00898-20</u>. PMID: 33139275
- Xi R, Hadjipanayis AG, Luquette LJ, Kim TM, Lee E, Zhang J, Johnson MD, Muzny DM, Wheeler DA, Gibbs RA, Kucherlapati R, Park PJ. 2011. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. *Proc Natl Acad Sci USA* 108:E1128-1136. DOI: <a href="https://doi.org/10.1073/pnas.1110574108">https://doi.org/10.1073/pnas.1110574108</a>. PMID: 22065754
- Xiong A, Prakash P, Gao X, Chew M, Tay IJJ, Woodrow CJ, Engelward BP, Han J, Preiser PR. 2020. K13mediated reduced susceptibility to artemisinin in *Plasmodium falciparum* is overlaid on a trait of enhanced DNA damage repair. *Cell Rep* 32:107996. DOI: <u>https://doi.org/10.1016/j.celrep.2020.107996</u>.
   PMID: 32755588
- Yang T, Yeoh LM, Tutor MV, Dixon MW, McMillan PJ, Xie SC, Bridgford JL, Gillett DL, Duffy MF, Ralph SA,
   McConville MJ, Tilley L, Cobbold SA. 2019. Decreased K13 abundance reduces hemoglobin catabolism
   and proteotoxic stress, underpinning artemisinin resistance. *Cell Rep* 29:2917-2928 e2915. DOI:
   https://doi.org/10.1016/j.celrep.2019.10.095. PMID: 31775055
- 916

## 917 Legends

918 Figure 1. Frequency and distribution of *K13* alleles in 11 African countries.

Map of Africa with pie charts representing the proportions of sequenced samples per country that harbor the K13 wild-type sequence (3D7 reference), the R561H variant (the most commonly identified mutation, unique to Rwanda; see inset), or another less frequent non-synonymous K13 mutation. Sample sizes and years of sample collection are indicated. Mutations and numbers of African samples sequenced per country, and prior citations as appropriate, are listed in **Figure 1–source data 1**.

924

925 Figure 1–source data 1. Distribution of *K13* alleles over time in African countries (2011-2019).

926

#### 927 Figure 2. Gene-edited mutant K13 African parasites display variable levels of RSA survival.

(A-D) RSA survival rates for (A) 3D7 (Africa), (B) F32 (Tanzania), (C) UG659 (Uganda), or (D) UG815 (Uganda) 928 929 K13 wild-type parental lines and CRISPR/Cas9-edited K13 R561H, M579I or C580Y mutant clones. Unedited 930 parental lines are described in **Table 1** and **Supplementary file 4**. For 3D7, we also included a K13 wild-type 931 control (ctrl) line harboring silent shield mutations at the K13 gRNA cut site. Results show the percentage of 932 early ring-stage parasites (0-3 h post invasion) that survived a 6 h pulse of 700 nM DHA, relative to DMSO-933 treated parasites assayed in parallel. Percent survival values are shown as means ± SEM (detailed in Figure 2-934 source data 1). Results were obtained from 3 to 8 independent experiments, each performed in duplicate. P 935 values were determined by unpaired t tests and were calculated for mutant lines relative to the isogenic line expressing wild-type K13. \*\* P<0.01; \*\*\* P<0.001; \*\*\*\* P<0.0001. 936

937

938 Figure 2–source data 1. Ring-stage survival (RSA) assay data for K13 edited African parasites and 939 controls.

940

Figure 2-figure supplement 1. African K13 mutations result in reduced K13 protein levels in 3D7 parasites.

943 (A) Representative Western blot of parasite extracts probed with an anti-K13 monoclonal antibody (clone E9)
944 that recognizes full-length K13 (~85 kDa) and lower molecular weight bands, presumably N-terminal

degradation products, as previously reported (Gnadig *et al.*, 2020). Tightly synchronized K13 wild-type, R561H,
M579I or C580Y 3D7 parasites were harvested as 0-6 h ring stages. ERD2 was used as a loading control.
Experiments were performed on three independent occasions. (B) Quantification of K13 mutant protein levels
versus K13 wild-type protein levels across independent replicates, performed using ImageJ, with all protein
levels normalized to the ERD2 loading control. Western blots revealed reduced levels of K13 protein in the three
mutant lines relative to wild-type 3D7 parasites. Results are shown as means ± SEM. WT, wild-type.

951

Figure 2-figure supplement 1-source data 1. Raw figure files for K13 Western blots performed on 3D7
 parasites.

954

Figure 3. K13 mutations cause differential impacts on *in vitro* growth rates across gene-edited African
 strains.

(A-D) Percentage of mutant allele relative to the wild-type allele over time in (A) 3D7, (B) F32, (C) UG659, and
(D) UG815 parasite cultures in which K13 mutant clones were co-cultured at 1:1 starting ratios with isogenic
K13 wild-type controls over a period of 36 days. Results, shown as means ± SEM, were obtained from 2 to 5
independent experiments, each performed in duplicate. Values are provided in Figure 3-source data 1. (E)
The percent reduction in growth rate per 48 h generation, termed the fitness cost, is presented as mean ± SEM
for each mutant line relative to its isogenic wild-type comparator. (F) Fitness costs for mutant lines and isogenic
wild-type comparators plotted relative to RSA survival values for the same lines.

964

965 Figure 3–source data 1. Fitness assay data for *K13* edited African parasite lines and controls.

966

#### 967 Figure 4. The *K13* C580Y allele has progressively outcompeted all other alleles in Cambodia.

(A-D) Stacked bar charts representing the percentage of sequenced samples expressing the *K13* wild-type
 allele or individual variants, calculated based on the total number of samples (listed in parentheses) for a given
 period. Sample collection was segregated into four regions in Cambodia (detailed in Figure 4–figure
 supplement 1). All K13 mutant samples harbored a single non-synonymous nucleotide polymorphism.
 Mutations and numbers of Cambodian samples sequenced per region/year, including prior citations as
 appropriate, are listed in Figure 4–source data 1.

974

#### 975 Figure 4–source data 1. Distribution of *K13* alleles over time in Cambodia (2001-2017).

976

#### 977 Figure 4–figure supplement 1. Regions of sample collection in Cambodia for K13 sequencing.

- 978 Map depicting the four regions of Cambodia (western, northern, eastern, and southern) in which samples were 979 collected between 2001 and 2017 for K13 genotyping. Genotyping data are presented in **Figure 4**.
- 980

## 981 Figure 5. Southeast Asian K13 mutations yield elevated RSA survival and minor impacts on *in vitro* 982 growth in gene-edited parasite lines.

983 (A, B) RSA survival rates for Dd2 (Indochina) and Cam3.II (Cambodia) P. falciparum parasites expressing wild-984 type or mutant K13. Gene-edited parasites were generated using CRISPR/Cas9 or zinc-finger nucleases. 985 Control (ctrl) lines express silent shield mutations at the K13 gRNA cut site. Parental lines are described in 986 Table 1 and Supplementary file 4. Results show the percentage of early ring-stage parasites (0-3 h post 987 invasion) that survived a 6 h pulse of 700 nM DHA, relative to DMSO-treated parasites processed in parallel. 988 Percent survival values are shown as means ± SEM (detailed in Figure 5-source data 1). Results were 989 obtained from 3 to 13 independent experiments, each performed in duplicate. P values were determined by unpaired t tests and were calculated for mutant lines relative to the isogenic line expressing wild-type K13. 990 991 \*\*\* P<0.001; \*\*\*\* P<0.0001. (C) Percent reductions in growth rate per 48 h generation, expressed as the fitness cost, for each Dd2 mutant line relative to the Dd2<sup>WT</sup> line. Fitness costs were determined by co-culturing a 992 Dd2<sup>eGFP</sup> reporter line with either the Dd2 K13 wild-type parental line (Dd2<sup>WT</sup>) or gene-edited K13 mutant lines. 993 994 Co-cultures were maintained for 20 days and percentages of eGFP<sup>+</sup> parasites were determined by flow 995 cytometry (see Figure 5-source data 2 and Figure 5-figure supplement 1). Fitness costs were initially calculated relative to the Dd2<sup>eGFP</sup> reporter line (Figure 5-figure supplement 1) and then normalized to the 996 Dd2<sup>WT</sup> line. Mean ± SEM values were obtained from three independent experiments, each performed in 997 triplicate. (D) Fitness costs for K13 mutant lines, relative to the Dd2<sup>WT</sup> line, were plotted against their 998 999 corresponding RSA survival values.

1000

- 1001 Figure 5–source data 1. Ring-stage survival (RSA) assay data for *K13* edited SE Asian parasites and 1002 controls (Dd2 and Cam3.II strains).
- 1003

Figure 5–source data 2. Fitness assay data (percent eGFP+ parasites) for *K13* edited Dd2 parasites and parental control.

1006

# Figure 5-figure supplement 1. Southeast Asian K13 mutations result in minor in vitro growth defects in Dd2 parasites, with the exception of the C580Y and P553L mutations.

(A) Percentage of eGFP<sup>+</sup> parasites over time in parasite cultures in which an eGFP-expressing Dd2 line was cocultured in a 1:1 mixture with either the Dd2 K13 WT parental line (Dd2<sup>WT</sup>) or individual Dd2 gene-edited K13 mutant lines. Co-cultures were maintained over a period of 20 days, and the percentage of eGFP<sup>+</sup> parasites in each mix was determined by flow cytometry. Data are shown as means  $\pm$  SEM. Results were obtained from three independent experiments, each performed in triplicate. (B) Percent reduction in growth rate per 48 h generation, termed the fitness cost, for Dd2<sup>WT</sup> and K13-edited mutant lines relative to the Dd2<sup>eGFP</sup> line. Results are shown as means  $\pm$  SEM.

1016

### 1017 Figure 6. Thai isolates expressing mutant K13 display variable RSA survival rates.

1018 RSA survival rates for (A-E) *K13*-edited Thai isolates and (F) K13 E252Q unedited Thai lines, shown as means 1019  $\pm$  SEM (detailed in **Figure 6–source data 1**). Results were obtained from 3 to 7 independent experiments, each 1020 performed in duplicate. *P* values were determined by unpaired *t* tests and were calculated for mutant lines 1021 relative to the isogenic line expressing wild-type *K13*. \* *P*<0.05; \*\* *P*<0.01; \*\*\* *P*<0.001.

1022

Figure 6–source data 1. Ring-stage survival (RSA) assay data for *K13* edited Thai parasites and controls.

## 1025 Figure 7. Ferredoxin (fd) and multidrug resistance protein 2 (mdr2) mutations do not impact RSA 1026 survival or *in vitro* growth rates in K13 C580Y parasites.

1027 RSA survival rates for (A) RF7<sup>C580Y</sup> parasite lines expressing the fd variant D193Y (parent), this variant plus 1028 silent shield mutations (edited control), or fd D193 (edited revertant), and (C) Cam3.II<sup>C580Y</sup> parasite lines 1029 expressing the mdr2 variant T484I (parent), this variant plus silent shield mutations (edited control), or mdr2 1030 T484 (edited revertant). Parental lines are described in Table 1 and Supplementary file 4. Mean ± SEM 1031 survival rates were generated from three independent experiments, each performed in duplicate. (B, D) In vitro eGFP-based fitness assays performed with (B) fd and (D) mdr2 RF7<sup>C580Y</sup> or Cam3.II<sup>C580Y</sup> edited lines, 1032 respectively. Competitive growth assays were seeded with individual lines plus the Dd2<sup>eGFP</sup> reporter line at a 1033 1034 10:1 starting ratio. Results show the percentage of eGFP<sup>+</sup> parasites over time. Co-cultures were maintained 1035 over a period of 24 days (fd-edited lines) or 30 days (mdr2-edited lines) and percentages of eGFP<sup>+</sup> parasites 1036 were determined by flow cytometry. Results were obtained from 2-3 independent experiments, each performed 1037 in triplicate, and are shown as means ± SEM. All values are provided in Figure 7-source data 1-3.

1038

1039 Figure 7-source data 1. Ring-stage survival (RSA) assay data for fd and mdr2 edited parasites and 1040 controls.

1041

Figure 7-source data 2. Fitness assay data (percent eGFP+ parasites) for RF7 fd edited parasites and parental control.

1044

Figure 7-source data 3. Fitness assay data (percent eGFP+ parasites) for Cam3.II mdr2 edited parasites
 and parental control.

1047

## 1048 Figure 7–figure supplement 1. Ferredoxin (fd) and multidrug resistance protein 2 (mdr2) mutations do 1049 not impact RSA survival or *in vitro* growth in K13 C580Y parasites.

(A, B) Ring-stage survival assays (RSAs) performed on fd and mdr2 edited lines and parental controls (RF7<sup>C580Y</sup> 1050 and Cam3.II<sup>C580Y</sup>, respectively). Results show RSA survival rates across a range of DHA concentrations. 1051 1052 Survival rates were calculated relative to DMSO-treated parasites processed in parallel. Results were obtained 1053 from three independent experiments, each performed in duplicate. Data are shown as means ± SEM. (C, D) In vitro eGFP-based fitness assays performed with (C) fd and (D) mdr2 RF7<sup>C580Y</sup> or Cam3.II<sup>C580Y</sup> edited lines, 1054 respectively. Competitive growth assays were seeded with individual lines plus the Dd2<sup>eGFP</sup> reporter line at a 1055 1056 100:1 starting ratio. Results show the percentage of eGFP<sup>+</sup> parasites over time. Co-cultures were maintained over a period of 24 days (fd-edited lines) or 30 days (mdr2-edited lines) and percentages of eGFP<sup>+</sup> parasites 1057

- were determined by flow cytometry. Results were obtained from 2 to 3 independent experiments, each
  performed in triplicate, and are shown as means ± SEM.
- 1060

## 1061 Supplementary Files

Supplementary file 1. Sample information and approval from within-country ethics committees for K13
 genotyping data.

1064

## 1065 Supplementary file 2. CRISPR/Cas9 strategy for editing the *K13* locus.

1066 All-in-one plasmid approach used for CRISPR/Cas9-mediated K13 gene editing, consisting of a K13-specific 1067 donor template for homology-directed repair, a K13-specific gRNA expressed from the U6 promoter, a Cas9 1068 cassette with expression driven by the calmodulin (cam) promoter, and a selectable marker (human dhfr, 1069 conferring resistance to the antimalarial WR99210 that inhibits P. falciparum dhfr). The Cas9 sequence was 1070 codon-optimized for improved expression in P. falciparum. Donors coding for specific mutations of interest (e.g., 1071 K13 C580Y, red star) were generated by site-directed mutagenesis of the K13 wild-type donor sequence. Green 1072 bars indicate the presence of silent shield mutations that were introduced to protect the edited locus from further 1073 cleavage. The lightning bolt indicates the location of the cut site in the genomic target locus. Primers used for 1074 cloning and final plasmids are described in Supplementary files 7 and 8, respectively.

1075

## 1076 Supplementary file 3. Crystal structure of K13 propeller domain showing positions of mutated residues.

1077 (A, B) Top and (C, D) side views of the crystal structure of the K13 propeller domain (PDB ID: 4YY8),
1078 highlighting residues of interest (F446I, orange; R539T, dark blue; I543T, purple; P553L, pink; R561H, dark
1079 turquoise; P574L, light turquoise; M579I medium blue; C580Y, red). Structures shown in (A) and (C) show wild1080 type residues while (B) and (D) show mutated residues.

- 1081
- Supplementary file 4. Geographic origin and drug resistance genotypes of Plasmodium falciparum
   clinical isolates and reference lines employed in this study.

1084

- 1085 Supplementary file 5. Transgenic *Plasmodium falciparum* lines generated in this study.
- 1086

1087 Supplementary file 6. CRISPR/Cas9 strategy for editing the *ferredoxin (fd)* and *multidrug resistance* 1088 *protein 2 (mdr2)* loci.

1089 All-in-one plasmid approaches used for CRISPR/Cas9-mediated editing of (A) the ferredoxin (fd) locus or (B) the 1090 multidrug resistance protein 2 (mdr2) locus. Plasmids consisted of a fd (A) or mdr2 (B) specific donor template 1091 for homology-directed repair, a gene-specific gRNA expressed from the U6 promoter, a Cas9 cassette with 1092 expression driven by the *cam* promoter, and a selectable marker (human *dhfr*, conferring resistance to 1093 WR99210). Donors coding for specific mutations of interest (fd D193Y or mdr2 T484I) were generated by site-1094 directed mutagenesis of the wild-type donor sequences. Red bars indicate the presence of silent shield 1095 mutations used to protect edited loci from further cleavage. Primers used for cloning and final plasmids are 1096 described in **Supplementary files 7** and **8**, respectively.

1097

1098 Supplementary file 7. Oligonucleotides used in this study.

- 1099
- 1100 Supplementary file 8. Description of gene-editing plasmids generated in this study.
- 1101
- 1102 Supplementary file 9. Real-Time PCR (qPCR) primers and probes used in this study.


## 1103 Table 1. *Plasmodium falciparum* lines employed herein.


Parasite	Origin	Year	K13	Resistance
3D7 <sup>WT</sup>	Africa	1981	WT	
F32 <sup>WT</sup>	Tanzania	1982	WT	
UG659 <sup>WT</sup>	Uganda	2007	WT	CQ, SP
UG815 <sup>WT</sup>	Uganda	2008	WT	CQ, SP
Dd2 <sup>WT</sup>	Indochina	1980	WT	CQ, MFQ, SP
Cam3.II <sup>WT</sup>	Cambodia	2010	WT	CQ, SP
CamWT <sup>C580Y</sup>	Cambodia	2010	C580Y	ART, CQ, SP
RF7 <sup>C580Y</sup>	Cambodia	2012	C580Y	ART, CQ, PPQ, SP
Thai1 <sup>WT</sup>	Thailand	2003	WT	CQ, SP
Thai2 <sup>WT</sup>	Thailand	2004	WT	CQ, MFQ, SP
Thai3 <sup>WT</sup>	Thailand	2003	WT	CQ, SP
Thai4 <sup>WT</sup>	Thailand	2003	WT	CQ, SP
Thai5 <sup>WT</sup>	Thailand	2011	WT	CQ, SP
Thai6 <sup>E252Q</sup>	Thailand	2008	E252Q	ART (low), CQ, MFQ, SP
Thai7 <sup>E252Q</sup>	Thailand	2010	E252Q	ART (low), CQ, MFQ, SP


ART, artemisinin; CQ, chloroquine; MFQ, mefloquine; PPQ, piperaquine; SP, sulfadoxine/pyrimethamine; WT, wild type.


1104





















Figure 2–figure supplement 1



## Figure 4–figure supplement 1




Western Cambodia Battambang Pailin Pursat

Northern Cambodia Oddar Meanchey Preah Vihear Kampong Thom Siem Riep

Eastern Cambodia Stung Treng Ratanakiri Mondulkiri Kratie

Southern Cambodia Kampong Speu Kampot Preah Sihanouk

## Figure 5–figure supplement 1



# Figure 7–figure supplement 1

